US20080064645A1 - Non-Natural Sphingolipid Analogs and Uses Thereof - Google Patents
Non-Natural Sphingolipid Analogs and Uses Thereof Download PDFInfo
- Publication number
- US20080064645A1 US20080064645A1 US11/839,024 US83902407A US2008064645A1 US 20080064645 A1 US20080064645 A1 US 20080064645A1 US 83902407 A US83902407 A US 83902407A US 2008064645 A1 US2008064645 A1 US 2008064645A1
- Authority
- US
- United States
- Prior art keywords
- compound
- alkyl
- alkynyl
- alkenyl
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003408 sphingolipids Chemical class 0.000 title abstract description 15
- 210000004027 cell Anatomy 0.000 claims abstract description 121
- 238000000034 method Methods 0.000 claims abstract description 64
- 230000012202 endocytosis Effects 0.000 claims abstract description 59
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 46
- 102000006495 integrins Human genes 0.000 claims abstract description 46
- 108010044426 integrins Proteins 0.000 claims abstract description 46
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 230000011664 signaling Effects 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 241000700605 Viruses Species 0.000 claims abstract description 17
- 208000015181 infectious disease Diseases 0.000 claims abstract description 14
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 170
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 125000003342 alkenyl group Chemical group 0.000 claims description 37
- 125000000304 alkynyl group Chemical group 0.000 claims description 37
- 230000005764 inhibitory process Effects 0.000 claims description 37
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 36
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 36
- 150000001720 carbohydrates Chemical class 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 30
- 238000012360 testing method Methods 0.000 claims description 29
- 210000003979 eosinophil Anatomy 0.000 claims description 22
- -1 courmarin Chemical compound 0.000 claims description 20
- 108010022222 Integrin beta1 Proteins 0.000 claims description 18
- 102000012355 Integrin beta1 Human genes 0.000 claims description 18
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims description 17
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 17
- 230000004913 activation Effects 0.000 claims description 17
- 150000003248 quinolines Chemical class 0.000 claims description 17
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 241000233866 Fungi Species 0.000 claims description 11
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 claims description 8
- 102000001332 SRC Human genes 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 108010087686 src-Family Kinases Proteins 0.000 claims description 7
- 108010002616 Interleukin-5 Proteins 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 5
- TYCDGIBDMITBCH-UHFFFAOYSA-N 2-(dimethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(N(C)C)=CC=C21 TYCDGIBDMITBCH-UHFFFAOYSA-N 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 229910052796 boron Inorganic materials 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 4
- 210000001626 skin fibroblast Anatomy 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 125000005629 sialic acid group Chemical group 0.000 claims description 3
- 230000012292 cell migration Effects 0.000 claims description 2
- 108010059108 CD18 Antigens Proteins 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000004709 cell invasion Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 30
- 238000011282 treatment Methods 0.000 abstract description 24
- 230000006870 function Effects 0.000 description 26
- 0 [1*]C(=O)NC(CO[3*])[C@H]([2*])O Chemical compound [1*]C(=O)NC(CO[3*])[C@H]([2*])O 0.000 description 20
- 150000002632 lipids Chemical class 0.000 description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 230000003915 cell function Effects 0.000 description 14
- 235000014633 carbohydrates Nutrition 0.000 description 12
- 150000002339 glycosphingolipids Chemical class 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 10
- 108010067306 Fibronectins Proteins 0.000 description 9
- 102000016359 Fibronectins Human genes 0.000 description 9
- 210000004323 caveolae Anatomy 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 108010019874 Clathrin Proteins 0.000 description 8
- 102000005853 Clathrin Human genes 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229930193282 clathrin Natural products 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- TZMWEGONHIPMLS-XKZLPGLHSA-N C/C=C/[C@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(C)=O Chemical compound C/C=C/[C@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(C)=O TZMWEGONHIPMLS-XKZLPGLHSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 6
- 102100025304 Integrin beta-1 Human genes 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000009016 Cholera Toxin Human genes 0.000 description 5
- 108010049048 Cholera Toxin Proteins 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 102100025390 Integrin beta-2 Human genes 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 description 4
- 235000019800 disodium phosphate Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 229940100602 interleukin-5 Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 125000002577 pseudohalo group Chemical group 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 3
- PCRKJCCRBWHLNK-CVFRIXQASA-N C/C=C/[C@H](O)[C@H](COC1OC(CO)C(O)C(O)C1O)NC(C)=O Chemical compound C/C=C/[C@H](O)[C@H](COC1OC(CO)C(O)C(O)C1O)NC(C)=O PCRKJCCRBWHLNK-CVFRIXQASA-N 0.000 description 3
- UVGIMTFCJXWYCT-CTBHZHIVSA-N C/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(O)C(O)C2O)C(O)C1O)NC(=O)CCCC/C1=C/C=C2/C=C3C(C)=CC(C)=N3B(F)(F)N21 Chemical compound C/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(O)C(O)C2O)C(O)C1O)NC(=O)CCCC/C1=C/C=C2/C=C3C(C)=CC(C)=N3B(F)(F)N21 UVGIMTFCJXWYCT-CTBHZHIVSA-N 0.000 description 3
- SAUGDRAQVTXEOL-GLUSLMEWSA-N C/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(O)C(O)C2O)C(O)C1O)NC(C)=O Chemical compound C/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(O)C(O)C2O)C(O)C1O)NC(C)=O SAUGDRAQVTXEOL-GLUSLMEWSA-N 0.000 description 3
- NYAIZOKIDFHWIY-QZYMWWKDSA-N C/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3O)C(O)C2O)C(O)C1O)NC(C)=O Chemical compound C/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3O)C(O)C2O)C(O)C1O)NC(C)=O NYAIZOKIDFHWIY-QZYMWWKDSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- BJVMOYFSQVEGNH-UHFFFAOYSA-M CC(C)(C)C1OC(CO)C(O)C(O)C1O.CC(C)(C)C1OC(CO)C(O)C(O)C1O.CC(C)(C)C1OC(CO)C(O)C(OSOO[O-])C1O.CC(C)(C)C1OC(CO)C(OC2OC(CO)C(O)C(O)C2O)C(O)C1O.CC(C)(C)C1OC(CO)C(OC2OC(CO)C(O)C(O)C2O)C(O)C1O.CC(C)(C)C1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3O)C(O)C2O)C(O)C1O.CC(C)(C)P(=O)([O-])OCC[N+](C)(C)C Chemical compound CC(C)(C)C1OC(CO)C(O)C(O)C1O.CC(C)(C)C1OC(CO)C(O)C(O)C1O.CC(C)(C)C1OC(CO)C(O)C(OSOO[O-])C1O.CC(C)(C)C1OC(CO)C(OC2OC(CO)C(O)C(O)C2O)C(O)C1O.CC(C)(C)C1OC(CO)C(OC2OC(CO)C(O)C(O)C2O)C(O)C1O.CC(C)(C)C1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3O)C(O)C2O)C(O)C1O.CC(C)(C)P(=O)([O-])OCC[N+](C)(C)C BJVMOYFSQVEGNH-UHFFFAOYSA-M 0.000 description 3
- UAJFPHNOYNSOKY-UHFFFAOYSA-N CC(C)(C)C1OC(CO)C(OC2OC(CO)C(O)C(O)C2O)C(O)C1O Chemical compound CC(C)(C)C1OC(CO)C(OC2OC(CO)C(O)C(O)C2O)C(O)C1O UAJFPHNOYNSOKY-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VJLLLMIZEJJZTE-VNQXHBPZSA-N HexCer(d18:1/16:0) Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O VJLLLMIZEJJZTE-VNQXHBPZSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 150000002298 globosides Chemical class 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 230000003331 prothrombotic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- JIBQDTHZWOSCCZ-WKEYFYDBSA-N C/C=C/[C@H](O)[C@H](COC1OC(CO)C(O)C(OC2(C(=O)O)CC(O)C(NC(C)=O)C([C@H](O)[C@H](O)CO)O2)C1O)NC(C)=O Chemical compound C/C=C/[C@H](O)[C@H](COC1OC(CO)C(O)C(OC2(C(=O)O)CC(O)C(NC(C)=O)C([C@H](O)[C@H](O)CO)O2)C1O)NC(C)=O JIBQDTHZWOSCCZ-WKEYFYDBSA-N 0.000 description 2
- ARFGCLKUKWESNB-CRKINBQISA-N CCCCCCCCCCCCC/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(O)C(OC3(C(=O)O)CC(O)C(NC(C)=O)C([C@H](O)[C@H](O)CO)O3)C2O)C(O)C1O)NC(C)=O Chemical compound CCCCCCCCCCCCC/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(O)C(OC3(C(=O)O)CC(O)C(NC(C)=O)C([C@H](O)[C@H](O)CO)O3)C2O)C(O)C1O)NC(C)=O ARFGCLKUKWESNB-CRKINBQISA-N 0.000 description 2
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100025323 Integrin alpha-1 Human genes 0.000 description 2
- 102100032817 Integrin alpha-5 Human genes 0.000 description 2
- 102100032816 Integrin alpha-6 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 101150111584 RHOA gene Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000007000 Tenascin Human genes 0.000 description 2
- 108010008125 Tenascin Proteins 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960000510 ammonia Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229940043237 diethanolamine Drugs 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 108010028309 kalinin Proteins 0.000 description 2
- 150000003893 lactate salts Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 150000004701 malic acid derivatives Chemical class 0.000 description 2
- 210000002284 membrane microdomain Anatomy 0.000 description 2
- 229910052751 metal Chemical class 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 150000003890 succinate salts Chemical class 0.000 description 2
- 150000003892 tartrate salts Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150104494 CAV1 gene Proteins 0.000 description 1
- MVUJOSWIZJIVBY-PSBRJFJZSA-N CCCCCCCCCCCCC/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3CC(NC(C)=O)(OC4OC(CO)C(O)C(O)C4O)C(O)C(CO)O3)C(OC3(C(=O)O)CC(O)C(NC(C)=O)C([C@H](O)[C@H](O)CO)O3)C2O)C(O)C1O)NC(C)=O Chemical compound CCCCCCCCCCCCC/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3CC(NC(C)=O)(OC4OC(CO)C(O)C(O)C4O)C(O)C(CO)O3)C(OC3(C(=O)O)CC(O)C(NC(C)=O)C([C@H](O)[C@H](O)CO)O3)C2O)C(O)C1O)NC(C)=O MVUJOSWIZJIVBY-PSBRJFJZSA-N 0.000 description 1
- PGUYIHLFQOCHKH-UMFSFIPESA-N CCCCCCCCCCCCC/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(OC4OC(CO)C(O)C(O)C4O)C3NC(C)=O)C(OC3(C(=O)O)CC(O)C(NC(C)=O)C([C@H](O)[C@H](O)CO)O3)C2O)C(O)C1O)NC(C)=O Chemical compound CCCCCCCCCCCCC/C=C/[C@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(OC4OC(CO)C(O)C(O)C4O)C3NC(C)=O)C(OC3(C(=O)O)CC(O)C(NC(C)=O)C([C@H](O)[C@H](O)CO)O3)C2O)C(O)C1O)NC(C)=O PGUYIHLFQOCHKH-UMFSFIPESA-N 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 101710197658 Capsid protein VP1 Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 102000003727 Caveolin 1 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010069446 Fertilins Proteins 0.000 description 1
- 102000001133 Fertilins Human genes 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100032819 Integrin alpha-3 Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108010041341 Integrin alpha1 Proteins 0.000 description 1
- 108010055795 Integrin alpha1beta1 Proteins 0.000 description 1
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 1
- 108010072255 Integrin alpha3beta1 Proteins 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 101710169675 Major capsid protein VP1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229940122924 Src inhibitor Drugs 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006895 clathrin independent endocytosis Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- OKZIUSOJQLYFSE-UHFFFAOYSA-N difluoroboron Chemical compound F[B]F OKZIUSOJQLYFSE-UHFFFAOYSA-N 0.000 description 1
- OVTCUIZCVUGJHS-UHFFFAOYSA-N dipyrrin Chemical compound C=1C=CNC=1C=C1C=CC=N1 OVTCUIZCVUGJHS-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000008290 endocytic mechanism Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000000348 glycosyl donor Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 108010068609 integrin alpha 9 beta 1 Proteins 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010057670 laminin 1 Proteins 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- DONJGKADZJEXRJ-UHFFFAOYSA-N pentadec-1-yne Chemical compound CCCCCCCCCCCCCC#C DONJGKADZJEXRJ-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940112042 peripherally acting choline derivative muscle relaxants Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- CRDYSYOERSZTHZ-UHFFFAOYSA-M selenocyanate Chemical compound [Se-]C#N CRDYSYOERSZTHZ-UHFFFAOYSA-M 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003455 sulfinic acids Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
- C07F9/65324—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
Definitions
- the present invention was funded, in part, by the United States Public Health Service, Grant numbers GM-22942 and HL-083187; the United States government may have certain rights in this invention.
- This disclosure relates to modulation of cellular functions, and more particularly to the use of a non-natural sphingolipid analog to inhibit caveolar endocytosis, plasma membrane microdomain formation, transmembrane signaling, and integrin function, e.g., for therapeutic uses.
- Sphingolipids can participate in a wide variety of cellular functions, including cell-cell interactions, cell growth and differentiation, and signal transduction. SLs can interact with cholesterol to form membrane microdomains, and data from many studies suggest that the plasma membrane (PM) SL and cholesterol composition may be tightly regulated. To achieve this regulation, cells must balance complex processes such as endocytosis, recycling, intracellular sorting, and metabolism of SLs.
- caveolae flask-shaped invaginations at the PM that are enriched in SLs and cholesterol and are associated with the protein, caveolin-1 (Cav1).
- Caveolae may be involved in the uptake and/or binding of certain viruses (e.g., SV40), toxins (e.g., cholera toxin B subunit (CtxB)), fungi, bacteria, SLs, integrins, and albumin in various cell types.
- Membrane microdomains represent local regions of membranes that have a different overall composition from the bulk membrane and are thought to act as organizing centers to sequester particular lipids and proteins.
- Evidence for microdomains in various intracellular membranes comes from multiple approaches including “detergent insolubility” of membrane components, crosslinking of membrane proteins and lipids, biophysical studies of constrained lateral diffusion in membranes, energy transfer measurements to demonstrate “clustering” of labeled proteins in membranes, and EM studies to visualize local “enrichment” of particular proteins or lipids on membranes.
- Microdomain formation is thought to play a role in processes such as intracellular sorting and membrane signaling events. Caveolae (enriched in glycosphingolipids (GSLs) and cholesterol) are considered to be one type of PM microdomain.
- GSLs glycosphingolipids
- Integrins are a family of ⁇ heterodimeric membrane proteins at the PM which bind to extracellular matrix proteins and cell surface ligands, and are responsible for many types of cell adhesion events. Some integrins are internalized via caveolae or are present in lipid-enriched microdomains.
- kits for treating PM domains and inhibit caveolar endocytosis, transmembrane signaling, and integrin function are also provided.
- methods of treatment or amelioration of one or more symptoms of diseases and disorders associated with PM domain formation, caveolar endocytosis, transmembrane signaling, and integrin function include, but are not limited to, infection by various pathogens (e.g., certain bacteria, fungi, and viruses), cancer, multiple sclerosis, prothrombotic risk, ulcerative colitis, and renal disease.
- the compounds for use in the compositions and methods provided herein have Formula I: where the stereochemistry at carbons 2 and 3 can be (2S,3S) (i.e., L-threo) or (2R,3S) (i.e., L-erythro);
- R 1 is C 1-25 alkyl, C 2-25 alkenyl, C 2-25 alkynyl, C 2-25 aralkyl, C 2-25 heteroaralkyl, (C 1-20 alkyl)X, (C 2-20 alkenyl)X; or (C 2-20 alkynyl)X;
- X is a fluorophore;
- R 2 is C 1-25 alkyl, C 2-25 alkenyl, C 2-25 alkynyl, C 2-25 aralkyl, or C 2-25 heteroaralkyl;
- R 3 comprises carbohydrates and substituted choline derivatives.
- carbohydrates may include monosaccharides, disaccharides, oligosaccharides, carbohydrates containing one or more (e.g., 1, 2, 3, or 4) sialic acid residues, and carbohydrates containing sulfate esters.
- the anomeric carbon of the carbohydrate-containing group(s) can be linked to the sphingolipid backbone via a ⁇ -anomeric bond.
- R 3 may be selected from the group consisting of the formulae:
- R 1 is a C 6-22 alkyl (e.g., C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , and C 22 alkyl).
- R 1 is a (C 1-5 alkyl)X.
- X is selected from boron dipyrromethenedifluoride (BODIPY), 7-(4-nitrobenzo-2-oxa-1,3-diazole) (NBD), dimethylaminonaphthalenesulfonate (Dansyl), pyrene, rhodamine, courmarin, or fluorescein.
- BODIPY boron dipyrromethenedifluoride
- NBD 7-(4-nitrobenzo-2-oxa-1,3-diazole)
- Dansyl dimethylaminonaphthalenesulfonate
- pyrene pyrene
- rhodamine courmarin
- fluorescein fluorescein
- R 2 is a C 5-20 alkyl (e.g., C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , Cl 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , and C 20 alkyl).
- R 3 is a group of the formula:
- the compound of Formula I is ⁇ -D-lactosyl-N-octanoyl-L-threo-sphingosine or C8-L-threo-lactosylceramide (C8-LT-LacCer).
- the compound of Formula I is C8-L-threo-galactosylceramide (C8-LT-GalCer). In other embodiments, the compound of Formula I is C8-L-threo-globoside (C8-LT-Gb3). In some embodiments, the compound of Formula I is C8-L-threo-sphingomyelin (C8-LT-SM). In further embodiments, the compound of Formula I is C6-L-threo-sphingomyelin (C6-LT-SM). In one embodiment, the compound of Formula I is C8-L-threo-monosialohexosylganglioside (C8-LT-GM 4 ).
- the compound of Formula I is C8-L-threo-monosialodihexosylganglioside (C8-LT-GM 3 ). In some embodiments, the compound of Formula I is C8-L-threo-monosialotetrahexosylganglioside (C8-LT-GM 1 ). In another embodiment, the compound of Formula I is C5-BODIPY-L-threo-lactosylceramide (C5-BODIPY-LT-LacCer).
- Pharmaceutically-acceptable salts include, but are not limited to, amine salts, such as but not limited to N,N′-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1′-ylmethylbenzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc, aluminum, and other metal salts, such as but not limited to
- HSFS human skin fibroblasts
- GSLs glycosphingolipids
- treatment of HSFs with a natural lactosylceramide or an analog having an 8 carbon fatty acid and the natural, D-erythro, configuration of ceramide not only stimulated caveolar endocytosis, but also promoted formation of PM microdomains, and induced clustering and activation of 1-integrin within those domains.
- C8-DE-LacCer a natural lactosylceramide or an analog having an 8 carbon fatty acid and the natural, D-erythro, configuration of ceramide
- Treatment with exogenous SLs has thus been postulated to promote the formation of PM microdomains, which in turn induce the clustering and “activation” of certain transmembrane proteins, and a subsequent “signaling cascade” that promotes caveolar endocytosis (see FIG. 1 ).
- a non-natural GSL may prevent PM microdomain formation and inhibit both transmembrane signaling (e.g., integrin signaling or function) and caveolar endocytosis.
- a compound of Formula I may selectively block ⁇ 1-integrin clustering and activation within plasma membrane microdomains in cells (e.g., HSFs). This inhibition can also occur in the presence of a kinase activating antibody.
- a compound of Formula I may inhibit ⁇ 2-integrins, which may result in the inhibition of superoxide production in combination with IL-5 treatment in cells (e.g., human eosinophils).
- the compound of Formula I may be used to treat diseases in a mammal in which caveolar endocytosis, plasma membrane microdomain formation, transmembrane signaling, or integrin function are implicated.
- inhibiting caveolar endocytosis may result in the inhibition of infection and/or binding of a cell by certain bacterium, fungus, or virus species (e.g., SV40 virus).
- virus species e.g., SV40 virus.
- the compound of Formula I may be able to treat diseases associated with integrin function (e.g., inflammatory diseases, cancer, multiple sclerosis, prothrombotic risk, ulcerative colitis, and renal disease).
- the compound of Formula I may be used as a tool in which to determine whether or not a test compound is capable of restoring an inhibited function (e.g., caveolar endocytosis or plasma membrane microdomain formation) by contacting a cell with a compound of Formula I and the test compound.
- a test compound capable of restoring an inhibited function (e.g., caveolar endocytosis or plasma membrane microdomain formation) by contacting a cell with a compound of Formula I and the test compound.
- the cell is first contacted with the compound of Formula I, while in other embodiments the test compound makes the initial contact with the cell.
- a cell is contacted with a compound of Formula I and the level of a cellular function (e.g., caveolar endocytosis) is determined. The cell is then contacted with the test compound and the level of the cellular function is again measured.
- a cellular function e.g., caveolar endocytosis
- each of the measurements is compared to the results obtained from a control cell (e.g., a cell contacted with a derivative of the compound of Formula I having D-erythro or D-threo stereochemistry).
- a test compound may be able to promote infection and/or binding of a cell by a virus (e.g., to aid in gene therapy) in the presence of a compound of Formula I.
- a change in the cellular function may indicate that the test compound is capable of overcoming the modulation brought forth by the compound of Formula I; while in other embodiments, a change in the cellular function may instead indicate that a process other than the one being measured is operative for the test compound (e.g., the test compound may be able to enter the cell through a route other than caveolar endocytosis).
- FIG. 1 is a model demonstrating stimulation of caveolar endocytosis by exogenous SLs (including exogenous GSLs).
- Exogenous GSLs or cholesterol promote formation of microdomains (circle in center).
- Transmembrane proteins e.g., ⁇ 1-integrins, tetraspanins, or other molecules
- FIG. 2 demonstrates that the LT-isomer of C8-LacCer acts as a “dominant negative lipid,” selectively inhibiting caveolar endocytosis in HSFs.
- HSFs were either untreated (Control) or treated for 30 min at 110° C. with D-erythro or L-threo-C8-LacCer, and then pulse labeled with fluorescent albumin or ⁇ 1-integrin Fab (caveolar markers), Tfn (clathrin marker), dextran (fluid phase marker), or anti-IL2R Fab (for RhoA pathway).
- FIG. 3 demonstrates C8-LT-LacCer inhibition of PM domain formation.
- PM domains enriched in GM 1 ganglioside (A,B) or cholesterol (C) were visualized using fluorescent CtxB or BC- ⁇ , respectively. Clustering of these probes was induced using an anti-CtxB Ab or SV40. Note the inhibition of microdomain clustering when cells were pretreated with C8-LT-LacCer, compared to untreated control samples.
- A HSFs
- B,C CV1 cells. Bars, 10 ⁇ m.
- FIG. 4 demonstrates activation of ⁇ 1-integrin and stimulation of src kinase is inhibited by C8-LT-LacCer.
- HSFs were serum-starved for 2-3 hrs and then either untreated (panel 1 , Control) or incubated with a stimulating ⁇ 1-integrin IgG (panel 2 ; ⁇ 1-stim) or with the LacCer isomers (panels 3 & 4 ) for 30 min at 10° C. All samples were then warmed for 30 sec at 37° C., fixed and stained with HUTS-4 Ab that recognizes ⁇ 1-integrin in its active conformation. Note the absence of ⁇ 1-integrin activation in cells pretreated with C8-LT-LacCer. Quantitation in (B) was by image analysis (n ⁇ 10 cells/condition; 3 independent experiments). Bars, 10 ⁇ m.
- FIG. 5 demonstrates the effect of C8-LacCer stereoisomers on src activation.
- HSFs were treated with C8-DE-LacCer ( ⁇ PP2), C8-LT-LacCer, PDGF, or with ⁇ 1 stim Ab ⁇ LacCer isomers.
- Samples were warmed for 30 sec at 37° C., lysed, and the cell lysates blotted for src and phosphor-Src (Y416).
- FIG. 6 structures of fluorescent lipid analogs.
- various headgroups (R) were attached to BODIPY-ceramide, resulting in BODIPY-GalCer, -LacCer, -MalCer, -globoside, -sulfatide, or GM 1 .
- BODIPY-LacCer analogs were also synthesized using various chain length (C 12 , C 16 , C 18 , or C 20 ) sphingosines of BODIPY-fatty acids (C 3 vs. C 5 spacer). Fluorescent LacCer bearing an NBD-fatty acid (see B) in place of the BODIPY-fatty acid was also synthesized.
- B Structure of the D-isomer of NBD-labeled PC, a glycerolipid.
- FIG. 7 demonstrates inhibition of SV40 infection and binding by C8-LT-LacCer.
- C, D CV1 cells were treated with SV40 for 1 hr as in (A,B) and SV40 binding to live cells was detected using anti-SV40 VP1 MAb. Values in D are mean ⁇ SD (n ⁇ 20 cells from two independent experiments). Bars, 10 ⁇ m.
- modulating means any manner in which one or more cellular functions are inhibited, suppressed, modified, moderated, restored, increased or decreased in activity or otherwise altered as compared to a control or other test cell. Modulation also encompasses any change which is initiated by the administration of any pharmaceutical containing the composition described herein, such as use for treating diseases or disorders where the modulation of cellular function is implicated.
- alkyl As used herein, “alkyl,” “alkenyl” and “alkynyl” carbon chains, if not specified, contain from 1 to 25 carbons, or 1 or 2 to 22 carbons (e.g., 8-16, 5-15, 2-8, 6-12, 8-22, 6-22 and 10-18), and are straight or branched, substituted or unsubstituted. Alkenyl carbon chains of from 2 to 25 carbons, in certain embodiments, contain 1 to 8 double bonds and alkenyl carbon chains of 2 to 22 carbons, in certain embodiments, contain 1 to 5 double bonds.
- Exemplary alkyl, alkenyl and alkynyl groups herein include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, n-butyl, sec-butyl, tert-butyl, isopentyl, neopentyl, tert-pentyl, isohexyl, allyl (propenyl) and propargyl (propynyl).
- Substitutions may include, but are not limited to, halo, pseudohalo, alkyl, alkoxy, cycloalkyl, aryl, heteroaryl, amino, hydroxy, alkoxycarbonyl, hydroxycarbonyl, and fluorescent fatty acids, for example, dipyrromethene boron difluoride (BODIPY), 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD), dimethylaminonaphthalenesulfonate (Dansyl), pyrene, rhodamine, courmarin, or fluorescein.
- BODIPY dipyrromethene boron difluoride
- NBD 7-nitrobenz-2-oxa-1,3-diazol-4-yl
- Dansyl dimethylaminonaphthalenesulfonate
- pyrene pyrene, rhodamine, courmarin, or fluorescein.
- aryl refers to aromatic monocyclic or multicyclic groups containing from 6 to 19 carbon atoms.
- Aryl groups include, but are not limited to groups such as unsubstituted or substituted phenyl and unsubstituted or substituted naphthyl.
- heteroaryl refers to a monocyclic or multicyclic aromatic ring system, in certain embodiments, of about 5 to about 15 members where one or more, in one embodiment 1 to 3, of the atoms in the ring system is a heteroatom, that is, an element other than carbon, including but not limited to, nitrogen, oxygen or sulfur.
- the heteroaryl group may be optionally fused to a benzene ring.
- Heteroaryl groups include, but are not limited to, furyl, imidazolyl, pyrimidinyl, tetrazolyl, thienyl, pyridyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolinyl and isoquinolinyl.
- halo refers to F, Cl, Br or I.
- pseudohalides or pseudohalo groups are groups that behave substantially similar to halides. Such compounds can be used in the same manner and treated in the same manner as halides. Pseudohalides include, but are not limited to, cyanide, cyanate, thiocyanate, selenocyanate, trifluoromethoxy, and azide.
- cycloalkyl refers to a saturated mono- or multi-cyclic ring system, in certain embodiments of 3 to 10 carbon atoms, in other embodiments of 3 to 6 carbon atoms.
- hydroxycarbonyl refers to —COOH
- alkoxycarbonyl refers to —C(O)OR in which R is alkyl, including lower alkyl.
- alkoxy refers to RO— in which R is alkyl, including lower alkyl.
- amino refers to H 2 N— and “hydroxyl” refers to HO—.
- aralkyl refers to an alkyl group in which one of the hydrogen atoms of the alkyl is replaced by an aryl group.
- heteroarylkyl refers to an alkyl group in which one of the hydrogen atoms of the alkyl is replaced by a heteroaryl group.
- pharmaceutically acceptable derivatives of a compound include salts, esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, solvates, hydrates or prodrugs thereof. Such derivatives may be readily prepared by those of skill in this art using known methods for such derivatization. The compounds produced may be administered to animals or humans without substantial toxic effects and either are pharmaceutically active or are prodrugs.
- salts include, but are not limited to, amine salts, such as but not limited to N,N′-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1′-ylmethyl-benzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc; and other metal salts, such as but not limited to sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, nitrates, borates, methanesulf
- esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl and heterocyclyl esters of acidic groups, including, but not limited to, carboxylic acids, phosphoric acids, phosphinic acids, sulfonic acids, sulfinic acids and boronic acids.
- Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more solvent or water molecules, or I to about 100, or 1 to about 10, or one to about 2, 3 or 4, solvent or water molecules.
- treatment means any manner in which one or more of the symptoms of a disease or disorder are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein, such as use for treating diseases or disorders in which caveolar endocytosis, PM microdomain formation, transmembrane signaling, or integrin function is implicated.
- amelioration of the symptoms of a particular disorder by administration of a particular compound or pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.
- This disclosure is directed to the use of non-natural sphingolipids, the compounds of Formula I, for the inhibition of caveolar endocytosis, plasma membrane microdomain formation, transmembrane signaling and integrin function, including for the treatment, prevention, or amelioration of a disease associated with these cellular functions.
- the disclosure demonstrates that certain SLs, including those with D-erythro or D-threo stereochemistry, may regulate caveolar endocytosis by inducing the clustering of integrins and other transmembrane (TM) proteins into PM domains, resulting in their activation and transmembrane signaling.
- TM transmembrane
- the compounds of Formula I prevent PM microdomain formation and inhibit integrin signaling and caveolar endocytosis.
- a compound of Formula I selectively blocks ⁇ 1-integrin clustering and activation in HSFs, and may inhibit superoxide production in combination with IL-5 treatment in human eosinophils.
- the use of the compounds of Formula I can be extended to other cells types where inhibition of caveolar endocytosis, PM microdomain formation, transmembrane signaling and integrin function may have significant effects on inflammatory responses (e.g., asthma, allergy), cell migration and invasiveness (e.g., of cancerous or precancerous cells), and infection by certain bacteria, fungi, and viruses.
- the compounds for use in the compositions and methods provided herein have Formula I: where the stereochemistry at carbons 2 and 3 can be (2S,3S) (i.e., L-threo), (2R,3S) (i.e., L-erythro), (2S,3R) (i.e., D-erythro), or (2R,3R) (i.e., D-threo);
- R 1 can be C 1-25 alkyl, C 2-25 alkenyl, C 2-25 alkynyl, C 2-25 aralkyl, C 2-25 heteroaralkyl, (C 1-20 alkyl)X, (C 2-20 alkenyl)X; or (C 2-20 alkynyl)X;
- X can be any fluorophore;
- R 2 can be C 1-25 alkyl, C 2-25 alkenyl, C 2-25 alkynyl, C 2-25 aralkyl, or C 2-25 heteroaralkyl.
- R 3 can be a carbohydrate or substituted choline derivative.
- carbohydrates include monosaccharides (e.g., glucose, fructose, ribose, and galactose), disaccharides (e.g., sucrose, lactose, and maltose), oligosaccharides, gangliosides, carbohydrates containing one or more sialic acid residues (e.g., 1, 2, 3, or 4 sialic acid residues), and carbohydrates containing sulfate esters.
- R 3 is selected from the group consisting of the formulae:
- R 1 is a C 1-25 alkyl (e.g., C 1-10 , C 2-12 , C 4-16 , C 8-10 , Cl 10-12 , C 8-12 , C 12-16 , C 14-16 , C 11-15 , C 13-16 , C 10-20 , C 12-24 , C 8-22 , C 15-25 , and C 18-24 ).
- R 1 is a C 8-22 alkyl.
- R1 is (C 1-5 alkyl)X.
- X is selected from boron dipyrromethenedifluoride (BODIPY), 7-(4-nitrobenzo-2-oxa-1,3-diazole) (NBD), dimethylaminonaphthalenesulfonate (Dansyl), pyrene, rhodamine, courmarin, or fluorescein.
- BODIPY boron dipyrromethenedifluoride
- NBD 7-(4-nitrobenzo-2-oxa-1,3-diazole)
- Dansyl dimethylaminonaphthalenesulfonate
- pyrene rhodamine, courmarin, or fluorescein.
- X is BODIPY.
- R 2 is a C 5-20 alkyl (e.g., C 5-10 , C 6-12 , C 5-7 , C 10-15 , C 6-9 , C 8-14 , C 11-15 , C 10-20 , C 12-18 , C 14-20 ,
- R 3 is a group of the formula:
- the compound of Formula I is ⁇ -D-lactosyl-N-ocatnoyl-L-threo-sphingosine or C8-L-threo-lactosylceramide (C8-LT-LacCer).
- the compound of Formula I is C8-L-erythro-lactosylceramide (C8-LE-LacCer).
- the compound of Formula I is C8-L-threo-galactosylceramide (C8-LT-GalCer).
- the compound of Formula I is C8-L-erythro-galactosylceramide (C8-LE-GalCer). In other embodiments, the compound of Formula I is C8-L-threo-globoside (C8-LT-Gb3). In further embodiments, the compound of Formula I is C8-L-erythro-globoside (C8-LE-Gb3). In some embodiments, the compound of Formula I is C8-L-threo-sphingomyelin (C8-LT-SM). In certain embodiments, the compound of Formula I is C8-L-erythro-sphingomyelin (C8-LE-SM).
- the compound of Formula I is C6-L-threo-sphingomyelin (C6-LT-SM). In other embodiments, the compound of Formula I is C6-L-erythro-sphingomyelin (C6-LE-SM). In one embodiment, the compound of Formula I is C8-L-threo-monosialohexosylganglioside (C8-LT-GM 4 ). In another embodiment, the compound of Formula I is C8-L-erythro-monosialohexosylganglioside (C8-LE-GM 4 ).
- the compound of Formula I is C8-L-threo-monosialodihexosylganglioside (C8-LT-GM 3 ). In certain embodiments, the compound of Formula I is C8-L-erythro-monosialodihexosylganglioside (C8-LE-GM 3 ). In some embodiments, the compound of Formula I is C8-L-threo-monosialotetrahexosylganglioside (C8-LT-GM 1 ). In other embodiments, the compound of Formula I is C8-L-erythro-monosialotetrahexosylganglioside (C8-LE-GM 1 ).
- the compound of Formula I is C5-BODIPY-L-threo-lactosylceramide (C5-BODIPY-LT-LacCer). In further embodiments, the compound of Formula I is C5-BODIPY-L-erythro-lactosylceramide (C5-BODIPY-DE-LacCer) or C5-BODIPY-D-threo-lactosylceramide (C5-BODIPY-LT-LacCer).
- compositions of this disclosure may be prepared by the procedure described by Liu, Y. et al. (see, Liu, Y. and Bittman, R. Chem. Phys. Lipids 2006, 142, 58.) In certain embodiments, the procedure may be modified as required to obtain the desired compounds.
- an appropriate acid may be used to obtain the correct substitution at R 1 (e.g., octanoic acid), various terminal alkynes may be used to account for the variation in R 2 (e.g., 1-pentadecyne), and the formula used at R 3 may be obtained through modification of reaction conditions, known to one of ordinary skill in the art, to obtain the appropriate configuration of the suitably activated glycosyl donor (e.g., trichloroacetimidate, molecular sieves and a solution of BF 3 .Et 2 O in CH 2 Cl 2 stirred overnight to obtain the lactosyl functionality).
- R 1 e.g., octanoic acid
- various terminal alkynes may be used to account for the variation in R 2 (e.g., 1-pentadecyne)
- the formula used at R 3 may be obtained through modification of reaction conditions, known to one of ordinary skill in the art, to obtain the appropriate configuration of the suitably activated glycosyl donor (e
- compositions provided herein may be further modified into a pharmaceutical composition, and may exist as a pharmaceutically acceptable salt or derivative.
- the pharmaceutical compositions provided herein contain therapeutically effective amounts of the compounds provided herein that is useful in the treatment or amelioration of one or more of the symptoms of diseases or disorders associated with caveolar endocytosis, PM microdomain formation, transmembrane signaling and integrin function, or in which caveolar endocytosis, PM microdomain formation, transmembrane signaling and integrin function is implicated, and a pharmaceutically acceptable carrier.
- Diseases or disorders associated with caveolar endocytosis, PM microdomain formation, transmembrane signaling and integrin function include, but are not limited to, inflammatory diseases and cancer.
- Pharmaceutical carriers suitable for administration of the compounds provided herein includes any such carriers known to those skilled in the art to be suitable for the particular mode of administration.
- the compound may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients.
- the compounds are, in one embodiment, formulated into suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for parenteral administration, as well as transdermal patch preparation, dry powder inhalers, or aerosols.
- suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for parenteral administration, as well as transdermal patch preparation, dry powder inhalers, or aerosols.
- a compound as described above is formulated into a pharmaceutical composition using techniques and procedures well known in the art (see, e.g., Ansel Introduction to Pharmaceutical Dosage Forms, Fourth Edition 1985, 126).
- compositions effective concentrations of a compound or pharmaceutically acceptable derivative thereof is mixed with a suitable pharmaceutical carrier.
- the compound may be derivatized as the corresponding salt, ester, acetal, ketal, orthoesters hemiacetal, hemiketal, acid, base, solvate, or hydrate.
- concentrations of the compound in the composition is effective for delivery of an amount, upon administration, that treats or ameliorates one or more of the symptoms of diseases or disorders associated with integrin function or in which integrin function is implicated.
- compositions are formulated for single dosage administration.
- the weight fraction of compound is dissolved, suspended, dispersed or otherwise mixed in a selected carrier at an effective concentration such that the treated condition is relieved or one or more symptoms are ameliorated.
- the active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated.
- the therapeutically effective concentration may be determined empirically by testing the compounds in in vitro and in vivo systems and then extrapolating to dosages for humans.
- the concentration of active compound in the pharmaceutical composition will depend on absorption, inactivation and excretion rates of the active compound, the physicochemical characteristics of the compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art.
- the amount that is delivered is sufficient to ameliorate one or more of the symptoms of diseases or disorders associated with integrin function or in which integrin function is implicated, as described herein.
- the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
- solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN®, or dissolution in aqueous sodium bicarbonate.
- cosolvents such as dimethylsulfoxide (DMSO)
- surfactants such as TWEEN®
- dissolution in aqueous sodium bicarbonate aqueous sodium bicarbonate.
- the compound of Formula I may be utilized with a carrier.
- Potential carriers may include alcohol, DMSO, serum album, and artificial lipid vesicles (e.g., Liposomes), which may or may not contain other lipids (e.g., phosphatidylcholine). This latter method may be particularly useful in certain embodiments where in vivo delivery via airways is utilized.
- Derivatives of the compounds such as pharmaceutically acceptable salts of the compounds may also be used in formulating effective pharmaceutical compositions.
- the resulting mixture may be a solution, suspension, emulsion, or the like.
- the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle.
- the effective concentration is sufficient for ameliorating the symptoms of the disease, disorder or condition treated and may be empirically determined.
- the pharmaceutical compositions are provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds or pharmaceutically acceptable derivatives thereof.
- the pharmaceutically therapeutically active compounds and derivatives thereof are, in one embodiment, formulated and administered in unit-dosage forms or multiple-dosage forms.
- Unit-dose forms as used herein refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent.
- unit-dose forms include ampoules and syringes and individually packaged tablets or capsules. Unit-dose forms may be administered in fractions or multiples thereof.
- a multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pints or gallons. Hence, multiple dose form is a multiple of unit-doses which are not segregated in packaging.
- Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension.
- a carrier such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension.
- the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.
- nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.
- the exposure of cells to a compound of Formula I results in an inhibition of caveolar endocytosis, PM microdomain formation, transmembrane signaling, and/or integrin function within exposed cells.
- Introduction of the composition can be made in vivo or in vitro and may include incubation or exposure of the cells to a pure compound of Formula I, or may instead include other compounds or solutions (e.g., water, buffers, antibodies, interleukins, fluorescently-labeled cellular components, alcohols, DMSO, serum album, liposomes, and/or lipids).
- Any cell type may be used, and may include fibroblasts, eosinophils, epithelials, ciliated, muscle, erythrocytes, leukocytes, neurons, oligodendrocytes, stem cells, as well as cancer cells from, for example, ovarian, small lung cell carcinomas, glioblastoma, and prostate tumors.
- a change or modulation to the aforementioned cellular functions may be determined through the comparison of cellular function within similar cells which have been left untreated, as a control, or exposed to an SL of known function, for example, C8-DE-LacCer.
- inhibition of cellular functions may include inhibition of one or more of the following: plasma membrane microdomain formation; integrin clustering and activation within plasma membrane microdomains; caveolar endocytosis, src kinase activity, superoxide production, and degranulation.
- the integrin inhibited by a compound of Formula I may include, but is not limited to, those listed in Table 1 (adapted from Faull, R. J. and Ginsberg, M. H., J. Am. Soc. Nephrol 1996, 7, 1091.). For example, treatment of HSFs with C8-LT-LacCer, inhibits ⁇ 1-integrin, preventing caveolar endocytosis.
- Integrin Family a (adapted from Faull, R. J. et al., J. Am. Soc. Nephrol. 1996, 7, 1091.) Integrin Alternative Name(s) Ligand(s) Distribution ⁇ 1 ⁇ 1 VLA-1, CD49a/CD29 Collagen, laminin Broad ⁇ 2 ⁇ 1 VLA-2, CD49b/CD29 Collagen, laminin Broad ⁇ 3 ⁇ 1 VLA-3, CD49c/CD29 Laminin-5, fibronectin, Broad collagen ⁇ 4 ⁇ 1 VLA4, CD49d/CD29 Fibronectin, VCAM-1 Lymphocytes, muscle, monocytes/macrophages, neutral crest cells, fibroblasts ⁇ 5 ⁇ 1 VLA-5, CD49e/CD29 Fibronectin Broad ⁇ 6 ⁇ 1 VLA-6, CD49f/CD29 Laminin, fertilin Broad ⁇ 7 ⁇ 1 VLA-7 Laminin unknown ⁇ 8 ⁇ 1 VAL-8 Firbronectin, Neutral vitronecting, tenasc
- composition of Formula I can be used to treat, prevent, or ameliorate one or more symptoms of a disease associated with caveolar endocytosis, PM microdomain formation, transmembrane signaling, and/or integrin function in a mammal (e.g., a human, dog, pig, monkey, cat, mouse, rat, or horse).
- a mammal e.g., a human, dog, pig, monkey, cat, mouse, rat, or horse.
- inhibition of caveolar endocytosis could have significant effects on inflammatory responses, or the mobility of cancerous or precancerous cells.
- Diseases associated with an inflammatory response can include allergies, Alzheimer's, anemia, aortic valve stenosis, arthritis, cancer, congestive heart failure, fibromyalgia, fibrosis, heart attack, kidney failure, lupus, pancreatitis, psoriasis, stroke, and surgical complications.
- Caveolar endocytosis may also participate in the proliferation of various types of cancer (e.g., breast cancer, prostate cancer, skin cancer, lung cancer, leukemia, colon cancer, and Non-Hodgkin Lymphoma).
- Further applications of the compound of Formula I may include blocking the uptake and/or binding of particular pathogens by cells, as caveolae have been implicated in the uptake of certain viruses (e.g., SV40), toxins (e.g., chlolera toxin B subunit), fungi, bacteria, SLs, and albumins in various cell types.
- viruses e.g., SV40
- toxins e.g., chlolera toxin B subunit
- fungi fungi
- bacteria e.g., SLs, and albumins in various cell types.
- the composition of Formula I may be used to treat, prevent, or ameliorate one or more symptoms of a disease associated with integrin function in a mammal.
- Diseases linked to integrin function may include Multiple Sclerosis (see, e.g., Sheremata W. A. et al., CNS Drugs 2005; 19(11), 909), prothrombotic risk (see, e.g., Vijayan, K. V and Bray, P. F., Exp. Biol. Med. 2006, 231(5), 505), ulcerative colitis (see, e.g., Ferraccioli, G. F. et al., Eur. Rev. Med. Pharmacol., Sci. 2006, 10(1), 37), and renal disease (see, e.g., Blattner, S. M. and Kretzler, M., Curr Opin. Nephrol. Hypertens. 2005, 14(4), 404).
- a compound of Formula I may be used to study cellular processes, for example, caveolar endocytosis. These lipids may be used to modulate plasma membrane microdomain formation and therefore the downstream processes reliant on this functionality. Inhibition may be initiated through exposure (e.g., contact, addition, etc) of cells to a compound of Formula I either in vitro or in vivo. In certain embodiments, additional components may be used in conjunction with the lipid to further explore cellular functions (e.g., antibodies, interleukins, fluorescently-labeled cellular components, and biological inhibitors of cellular processes).
- additional components may be used in conjunction with the lipid to further explore cellular functions (e.g., antibodies, interleukins, fluorescently-labeled cellular components, and biological inhibitors of cellular processes).
- a compound of Formula I may be used in conjunction with a test compound to determine if the test compound is capable of restoring an inhibited function (e.g., caveolar endocytosis or uptake of a pathogen) while in the presence of a compound of Formula I.
- an inhibited function e.g., caveolar endocytosis or uptake of a pathogen
- Any appropriate cells may be used with a compound of Formula I, depending on the purpose of the study. For example, eosinophils may be used to study the role of PM microdomain formation in the inflammatory response, while skin fibroblasts may be used to investigate the role of this process on various endocytic events.
- a compound of Formula I might be particularly effective in modulating tumor cell motility and invasiveness since integrins bind to extracellular matrix proteins and cell surface ligands and are responsible for many types of cell adhesion events.
- cancer cells from ovarian, small lung cell carcinomas, glioblastoma, and prostate tumors may be particularly useful.
- the non-natural (L-threo; LT) isomers of C8-LacCer and BODIPY-LacCer were synthesized.
- the latter was synthesized by the method detailed in Liu, Y., et al. Chem. Phys. Lipids, 2006, 142, 58 (referred to as Liu).
- C8-LT-LacCer was prepared through a modification of the methods used in Liu, where an activated for of octanoic acid was used in place of BODIPY-C 5 -NHS. HSFs were then either untreated (Control) or treated for 30 min at 10° C.
- the LT-lipid inhibited uptake of multiple caveolar markers in HSFs as shown in FIG. 2 ; compare C8-LT-LacCer (yellow bars) to the corresponding DE isomer (red bars), which stimulated caveolar uptake as noted above.
- BODIPY-DE-LacCer which is internalized via caveolae
- BODIPY-LT-LacCer was internalized primarily ( ⁇ 65-70%) by clathrin-dependent endocytosis (data not shown). This result is particularly significant because selective inhibition of this pathway may have important applications in basic studies of endocytosis and in blocking uptake of particular pathogens by cells.
- CV1 cells were then incubated at low temperature with SV40 virus and it was found that this treatment induced the formation of PM domains enriched in GM 1 ganglioside and cholesterol, ( FIG. 3B ,C, left vs. middle) remarkably similar to the clustered microdomains induced by CtxB crosslinking ( FIG. 3A ).
- pretreatment of CV1 cells with C8-LT-LacCer prevented the SV40 induction of these PM domains ( FIG. 3B ,C, right panels).
- C8-LT-LacCer might inhibit caveolar internalization is by disruption transmembrane signaling events required for endocytosis.
- Signaling through ⁇ 1-integrin was studied because this integrin is internalized via caveolae in HSFs and other cell types (see Sharma, D. K. et al., Cancer Res. 2005, 65, 8233; and Upla, P. et al., Mol. Biol. Cell 2004, 15, 625), and because an early event following integrin activation is signaling through src, a kinase whose activity is required for caveolar endocytosis (see, e.g., Mineo, C. and Anderson, R. G., Histochem. Cell Biol.
- the first examination involved the activation of ⁇ 1-integrin in HSFs following crosslinking with a stimulatory Ab ( ⁇ 1-stim Ab) using the HUTS-4 Ab which only binds to ⁇ 1-integrins in their activated conformation (see, e.g., Luque, A. et al., J. Biol. Chem. 1996, 271, 11067). Treatment with the stimulatory Ab dramatically increased HUTS binding ( FIG.
- Human eosinophils were purified from normal individuals or patients with mild allergy by Percoll density gradient centrifugation and magnetic cell sorting using MACS anti-CD16 microbeads as described by Hansel T. T., et al., J. Immunol. Methods 1991, 145, 105. Briefly, after peripheral blood was overlaid on an isotonic Percoll solution (1.084 g.ml, Sigma), the blood was centrifuges at 1000 ⁇ g for 30 min at 4° C. Mononuclear cells at the interface were removed, and erythrocytes in sediment were lysed by two cycles of hypotonic water lysis.
- Percoll solution 1.084 g.ml, Sigma
- Isolated granulocytes were washed twice in PIPES buffer (25 mM PIPES, 50 mM NaCl, 5 mM KCl, 25 mM NaOH, 5.4 mM glucose, pH 7.4) containing 1% alpha calf serum (HyClone Laboratories; Logan, Utah). Cells were then incubated with equal volume of anti-CD16 mAb MACS microbeads for 60 min at 4° C. with occasional gentle mixing. After 60 min of incubation on ice, cells were loaded onto the separation column positioned in the MACS magnetic field. Cells were eluted three times with 5 ml of PIPES buffer with 1% DCS.
- the purity of eosinophils counted by Randolph's stain was >98%.
- the contaminating cells were neutrophills, and no mononuclear cells or basophils were present. Purified eosinophils were used immediately for experiments.
- Cell suspension (100 ⁇ l) was dispensed onto the wells of 96-well tissue culture plates, followed by 100 ⁇ l of serial dilution of C8-DE-LacCer or medium alone.
- the reaction wells were measured for absorbance at 550 nm in a microplate autoreader (Thermomax, Molecular Devices, Menlo Park, Calif.), followed by repeated readings. Between absorbance measurements, the plate was incubated at 37° C. After incubation and repeated measurements of superoxide production at 37° C. and 5% CO 2 for 4 h, cell-free supernatants from 96-well tissue culture plates were collected, and stored at ⁇ 20° C.
- EDN eosinphil-derived neutrotoxin
- C8-DE-LacCer induces adhesion of eosinophils to tissue culture wells.
- Eosinophils incubated with C8-DE-LacCer were flattened and showed spindle shape with many pseudopods, suggesting integrin-mediated cellular adhesion.
- a large quantity of superoxide was produced by eosinophils stimulated with C8-DE-LacCer but not those incubated with medium alone.
- a granule protein, EDN was released into supernatants by eosinophils incubated with C8-DE-LacCer.
- C8-DE-LacCer Given the effects of C8-DE-LacCer on eosinophils superoxide anion generation and adhesion, it is anticipated that C8-LT-LacCer may have inhibitory effects on some of these processes.
- the structure of the fluorescent GSL analogs were systematically varied (see FIG. 6 ) and examined to determine the effect of these variations on the mechanism of analog internalization.
- the fluorescent analogs of GalCer, globoside, GM 1 , LacCer, MalCer, and sulfatide were used.
- Rat fibroblasts were incubated with each analog in the presence or absence of various inhibitors to differentiate clathrin-dependent from clathrin-independent endocytosis, and the amount of internalization (at 5 min) was quantified by image analysis.
- each GSL analog (GalCer, globoside, GM 1 , LacCer, MalCer, and sulfatide) was substantially inhibited by nystatin (but not by chlorpromazine (CPZ)), similar to BODIPY-LacCer (see Table 2), indicating that the specific carbohydrate headgroup structure or the stereochemistry of the glycosidic linkage in the disaccharide moiety of the GSL does not play a significant role in selective internalization of these GSLs by the clathrin-independent, caveolar mechanism.
- CPZ chlorpromazine
- NBD-labeled LacCer was studied, and it was found that its internalization was nystatin-inhibitable and CPZ-insensitive (see Table 2), similar to our findings for BODIPY-LacCer (and other BODIPY-GSLs). This demonstrated that the fluorophore (NBD vs. BODIPY) had no apparent influence on the internalization mechanism.
- C8-LT-LacCer treatment on SV40 infection in monkey CV1 cells was examined as endocytosis of this virus has been extensively characterized in this cell type and shown to occur via caveolae (Pelkman, L., et al. Nature Cell Biol. 2001, 3, 473; Anderson, H. A., et al., Mol. Biol. Cell 1996, 7, 1825; Stang, E., et al. Mol. Biol. Cell 1997, 8, 47.) CV1 cells were pretreated with the LacCer stereoisomers and SV40 at low temperature, washed, and shifted to 37° C. for 14 hrs. Pretreatment of cells with C8-LT-LacCer dramatically reduced the vial infection as monitored by the expression of the large T antigen, while C8-DE-LacCer had no effect relative to untreated control samples (see FIG. 7A , B).
- C8-LT-LacCer Since inhibition of SV40 infection by C8-LT-LacCer could result from effects on virus binding as well as endocytosis, we also studied the effect of C8-LT-LacCer on SV40 binding.
- Cells were treated with the C8-LT-LacCer isomer and SV40 at low temperature, washed, and then incubated with a monoclonal antibody to the SV40 major capsid protein VP1.
- C8-LT-LacCer inhibited SV40 binding to CV1 cells by about 80% (see FIG. 7C , D).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application claims priority under 35 U.S.C. §119 to U.S. Ser. No. 60/838,024, filed Aug. 15, 2006 and U.S. Ser. No. 60/908,903, filed Mar. 29, 2007, the contents of which are incorporated by reference in their entirety.
- The present invention was funded, in part, by the United States Public Health Service, Grant numbers GM-22942 and HL-083187; the United States government may have certain rights in this invention.
- This disclosure relates to modulation of cellular functions, and more particularly to the use of a non-natural sphingolipid analog to inhibit caveolar endocytosis, plasma membrane microdomain formation, transmembrane signaling, and integrin function, e.g., for therapeutic uses.
- Sphingolipids (SLs) can participate in a wide variety of cellular functions, including cell-cell interactions, cell growth and differentiation, and signal transduction. SLs can interact with cholesterol to form membrane microdomains, and data from many studies suggest that the plasma membrane (PM) SL and cholesterol composition may be tightly regulated. To achieve this regulation, cells must balance complex processes such as endocytosis, recycling, intracellular sorting, and metabolism of SLs.
- Several clathrin-independent mechanisms of endocytosis have been identified and actively studied in mammalian cells. One well-studied clathrin-independent mechanism is uptake via caveolae—flask-shaped invaginations at the PM that are enriched in SLs and cholesterol and are associated with the protein, caveolin-1 (Cav1). Caveolae may be involved in the uptake and/or binding of certain viruses (e.g., SV40), toxins (e.g., cholera toxin B subunit (CtxB)), fungi, bacteria, SLs, integrins, and albumin in various cell types.
- Membrane microdomains represent local regions of membranes that have a different overall composition from the bulk membrane and are thought to act as organizing centers to sequester particular lipids and proteins. Evidence for microdomains in various intracellular membranes comes from multiple approaches including “detergent insolubility” of membrane components, crosslinking of membrane proteins and lipids, biophysical studies of constrained lateral diffusion in membranes, energy transfer measurements to demonstrate “clustering” of labeled proteins in membranes, and EM studies to visualize local “enrichment” of particular proteins or lipids on membranes. Microdomain formation is thought to play a role in processes such as intracellular sorting and membrane signaling events. Caveolae (enriched in glycosphingolipids (GSLs) and cholesterol) are considered to be one type of PM microdomain.
- Integrins are a family of αβ heterodimeric membrane proteins at the PM which bind to extracellular matrix proteins and cell surface ligands, and are responsible for many types of cell adhesion events. Some integrins are internalized via caveolae or are present in lipid-enriched microdomains.
- Provided herein are compounds, compositions containing the compounds, and methods of use of the compounds useful to prevent formation of PM domains and inhibit caveolar endocytosis, transmembrane signaling, and integrin function. Also provided are methods of treatment or amelioration of one or more symptoms of diseases and disorders associated with PM domain formation, caveolar endocytosis, transmembrane signaling, and integrin function. Such diseases and disorders include, but are not limited to, infection by various pathogens (e.g., certain bacteria, fungi, and viruses), cancer, multiple sclerosis, prothrombotic risk, ulcerative colitis, and renal disease.
- In one embodiment, the compounds for use in the compositions and methods provided herein have Formula I:
where the stereochemistry atcarbons 2 and 3 can be (2S,3S) (i.e., L-threo) or (2R,3S) (i.e., L-erythro); R1 is C1-25 alkyl, C2-25 alkenyl, C2-25 alkynyl, C2-25 aralkyl, C2-25 heteroaralkyl, (C1-20 alkyl)X, (C2-20 alkenyl)X; or (C2-20 alkynyl)X; X is a fluorophore; R2 is C1-25 alkyl, C2-25 alkenyl, C2-25 alkynyl, C2-25 aralkyl, or C2-25 heteroaralkyl; R3 comprises carbohydrates and substituted choline derivatives. For example, carbohydrates may include monosaccharides, disaccharides, oligosaccharides, carbohydrates containing one or more (e.g., 1, 2, 3, or 4) sialic acid residues, and carbohydrates containing sulfate esters. In certain cases, the anomeric carbon of the carbohydrate-containing group(s) can be linked to the sphingolipid backbone via a β-anomeric bond. In addition, R3 may be selected from the group consisting of the formulae: - In some embodiments, R1 is a C6-22 alkyl (e.g., C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, and C22 alkyl). In other embodiments, R1 is a (C1-5 alkyl)X. In further embodiments, X is selected from boron dipyrromethenedifluoride (BODIPY), 7-(4-nitrobenzo-2-oxa-1,3-diazole) (NBD), dimethylaminonaphthalenesulfonate (Dansyl), pyrene, rhodamine, courmarin, or fluorescein. In some instances, X is BODIPY. In certain embodiments, R2 is a C5-20 alkyl (e.g., C5, C6, C7, C8, C9, C10, C11, Cl12, C13, C14, C15, C16, C17, C18, C19, and C20 alkyl). In other embodiments, R3 is a group of the formula:
In still further embodiments, the compound of Formula I is β-D-lactosyl-N-octanoyl-L-threo-sphingosine or C8-L-threo-lactosylceramide (C8-LT-LacCer).
In another embodiment, the compound of Formula I is C8-L-threo-galactosylceramide (C8-LT-GalCer).
In other embodiments, the compound of Formula I is C8-L-threo-globoside (C8-LT-Gb3).
In some embodiments, the compound of Formula I is C8-L-threo-sphingomyelin (C8-LT-SM).
In further embodiments, the compound of Formula I is C6-L-threo-sphingomyelin (C6-LT-SM).
In one embodiment, the compound of Formula I is C8-L-threo-monosialohexosylganglioside (C8-LT-GM4).
In certain embodiments, the compound of Formula I is C8-L-threo-monosialodihexosylganglioside (C8-LT-GM3).
In some embodiments, the compound of Formula I is C8-L-threo-monosialotetrahexosylganglioside (C8-LT-GM1).
In another embodiment, the compound of Formula I is C5-BODIPY-L-threo-lactosylceramide (C5-BODIPY-LT-LacCer). - Also provided are pharmaceutically acceptable derivatives, including salts, esters, solvates, hydrates and prodrugs of the compounds described herein. Pharmaceutically-acceptable salts, include, but are not limited to, amine salts, such as but not limited to N,N′-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1′-ylmethylbenzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc, aluminum, and other metal salts, such as but not limited to sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, salts of mineral acids, such as but not limited to hydrochlorides and sulfates; and salts of organic acids, such as but not limited to acetates, lactates, malates, tartrates, citrates, ascorbates, succinates, butyrates, valerates and fumarates.
- Previous studies have demonstrated that incubation of human skin fibroblasts (HSFS) with glycosphingolipids (GSLs) stimulates endocytosis of several caveolar markers (see, e.g., Sharma, D. K. et al., Molec. Biol. Cell 2004, 15, 3114 and Sharma, D. K. et al., Cancer Res. 2005, 65, 1). For example, treatment of HSFs with a natural lactosylceramide or an analog having an 8 carbon fatty acid and the natural, D-erythro, configuration of ceramide (referred to as C8-DE-LacCer herein) not only stimulated caveolar endocytosis, but also promoted formation of PM microdomains, and induced clustering and activation of 1-integrin within those domains. Treatment with exogenous SLs has thus been postulated to promote the formation of PM microdomains, which in turn induce the clustering and “activation” of certain transmembrane proteins, and a subsequent “signaling cascade” that promotes caveolar endocytosis (see
FIG. 1 ). For example, within these microdomains the activation of β1-integrin stimulates src kinase (phosphorylated at Y416), a result which is observed when HSFs are incubated with C8-DE-LacCer. In addition to stimulation of the β1-integrin in fibroblast cells, work with human eosinophils has shown that treatment with C8-DE-LacCer in combination with Interleukin-5 (IL-5) stimulated β2-integrins, results in increased superoxide production. - The present disclosure demonstrates, on the other hand, that a non-natural GSL, a compound of Formula I having the non-natural L-threo configuration of ceramide (e.g., C8-LT-LacCer), may prevent PM microdomain formation and inhibit both transmembrane signaling (e.g., integrin signaling or function) and caveolar endocytosis. In certain embodiments, a compound of Formula I may selectively block β1-integrin clustering and activation within plasma membrane microdomains in cells (e.g., HSFs). This inhibition can also occur in the presence of a kinase activating antibody. In other embodiments, a compound of Formula I may inhibit β2-integrins, which may result in the inhibition of superoxide production in combination with IL-5 treatment in cells (e.g., human eosinophils).
- Given the above, the compound of Formula I may be used to treat diseases in a mammal in which caveolar endocytosis, plasma membrane microdomain formation, transmembrane signaling, or integrin function are implicated. For example, inhibiting caveolar endocytosis may result in the inhibition of infection and/or binding of a cell by certain bacterium, fungus, or virus species (e.g., SV40 virus). In other embodiments, the compound of Formula I may be able to treat diseases associated with integrin function (e.g., inflammatory diseases, cancer, multiple sclerosis, prothrombotic risk, ulcerative colitis, and renal disease).
- In a further embodiment, the compound of Formula I may be used as a tool in which to determine whether or not a test compound is capable of restoring an inhibited function (e.g., caveolar endocytosis or plasma membrane microdomain formation) by contacting a cell with a compound of Formula I and the test compound. In some embodiments, the cell is first contacted with the compound of Formula I, while in other embodiments the test compound makes the initial contact with the cell. In certain embodiments, a cell is contacted with a compound of Formula I and the level of a cellular function (e.g., caveolar endocytosis) is determined. The cell is then contacted with the test compound and the level of the cellular function is again measured. Finally, the results of the two measurements are compared to determine whether or not the cellular function has increased or decreased between its exposure to the compound of Formula I and the test compound. In some embodiments, each of the measurements may be compared to the results obtained from a control cell (e.g., a cell contacted with a derivative of the compound of Formula I having D-erythro or D-threo stereochemistry). For example, a test compound may be able to promote infection and/or binding of a cell by a virus (e.g., to aid in gene therapy) in the presence of a compound of Formula I. In some embodiments, a change in the cellular function may indicate that the test compound is capable of overcoming the modulation brought forth by the compound of Formula I; while in other embodiments, a change in the cellular function may instead indicate that a process other than the one being measured is operative for the test compound (e.g., the test compound may be able to enter the cell through a route other than caveolar endocytosis).
- The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
-
FIG. 1 is a model demonstrating stimulation of caveolar endocytosis by exogenous SLs (including exogenous GSLs). Exogenous GSLs or cholesterol promote formation of microdomains (circle in center). Transmembrane proteins (e.g., β1-integrins, tetraspanins, or other molecules) cluster in these microdomains and undergo conformational changes, leading to signaling via src and perhaps other kinases that are required for caveolar endocytosis. -
FIG. 2 demonstrates that the LT-isomer of C8-LacCer acts as a “dominant negative lipid,” selectively inhibiting caveolar endocytosis in HSFs. HSFs were either untreated (Control) or treated for 30 min at 110° C. with D-erythro or L-threo-C8-LacCer, and then pulse labeled with fluorescent albumin or β1-integrin Fab (caveolar markers), Tfn (clathrin marker), dextran (fluid phase marker), or anti-IL2R Fab (for RhoA pathway). After 5 min at 37° C., cells were acid-stripped to remove non-internalized marker and images were acquired by fluorescence microscopy (A) and quantified (B). At least 20 cells for each condition were analyzed in multiple experiments. Bar, 10 μm. -
FIG. 3 demonstrates C8-LT-LacCer inhibition of PM domain formation. PM domains enriched in GM1 ganglioside (A,B) or cholesterol (C) were visualized using fluorescent CtxB or BC-⊖, respectively. Clustering of these probes was induced using an anti-CtxB Ab or SV40. Note the inhibition of microdomain clustering when cells were pretreated with C8-LT-LacCer, compared to untreated control samples. (A), HSFs; (B,C) CV1 cells. Bars, 10 μm. -
FIG. 4 . demonstrates activation of β1-integrin and stimulation of src kinase is inhibited by C8-LT-LacCer. HSFs were serum-starved for 2-3 hrs and then either untreated (panel 1, Control) or incubated with a stimulating β1-integrin IgG (panel 2; β1-stim) or with the LacCer isomers (panels 3 & 4) for 30 min at 10° C. All samples were then warmed for 30 sec at 37° C., fixed and stained with HUTS-4 Ab that recognizes β1-integrin in its active conformation. Note the absence of β1-integrin activation in cells pretreated with C8-LT-LacCer. Quantitation in (B) was by image analysis (n≧10 cells/condition; 3 independent experiments). Bars, 10 μm. -
FIG. 5 demonstrates the effect of C8-LacCer stereoisomers on src activation. HSFs were treated with C8-DE-LacCer (±PP2), C8-LT-LacCer, PDGF, or with β1 stim Ab±LacCer isomers. Samples were warmed for 30 sec at 37° C., lysed, and the cell lysates blotted for src and phosphor-Src (Y416). -
FIG. 6 structures of fluorescent lipid analogs. (A) various headgroups (R) were attached to BODIPY-ceramide, resulting in BODIPY-GalCer, -LacCer, -MalCer, -globoside, -sulfatide, or GM1. BODIPY-LacCer analogs were also synthesized using various chain length (C12, C16, C18, or C20) sphingosines of BODIPY-fatty acids (C3 vs. C5 spacer). Fluorescent LacCer bearing an NBD-fatty acid (see B) in place of the BODIPY-fatty acid was also synthesized. (B) Structure of the D-isomer of NBD-labeled PC, a glycerolipid. -
FIG. 7 demonstrates inhibition of SV40 infection and binding by C8-LT-LacCer. (A, B) CV1 cells were incubated LacCer stereoisomers for 30 min at 10° C., and then coincubated for 1 hr at 10° C. with SV40 virus (MOI=15). Samples were washed, incubated for 40 hrs in complete medium, fixed, permeabilized, and stained for the Large T antigen. Values in (B) are mean ±SD (n 250 cells/condition; three independent experiments). (C, D) CV1 cells were treated with SV40 for 1 hr as in (A,B) and SV40 binding to live cells was detected using anti-SV40 VP1 MAb. Values in D are mean ±SD (n≧20 cells from two independent experiments). Bars, 10 μm. - Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this invention belongs. All patents, applications, published applications and other publications are incorporated by reference in their entirety. In the event that there are a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.
- As used herein, modulating means any manner in which one or more cellular functions are inhibited, suppressed, modified, moderated, restored, increased or decreased in activity or otherwise altered as compared to a control or other test cell. Modulation also encompasses any change which is initiated by the administration of any pharmaceutical containing the composition described herein, such as use for treating diseases or disorders where the modulation of cellular function is implicated.
- As used herein, “alkyl,” “alkenyl” and “alkynyl” carbon chains, if not specified, contain from 1 to 25 carbons, or 1 or 2 to 22 carbons (e.g., 8-16, 5-15, 2-8, 6-12, 8-22, 6-22 and 10-18), and are straight or branched, substituted or unsubstituted. Alkenyl carbon chains of from 2 to 25 carbons, in certain embodiments, contain 1 to 8 double bonds and alkenyl carbon chains of 2 to 22 carbons, in certain embodiments, contain 1 to 5 double bonds. Alkynyl carbon chains of from 2 to 25 carbons, in certain embodiments, contain 1 to 8 triple bonds, and the alkynyl carbon chains of 2 to 22 carbons, in certain embodiments, contain 1 to 5 triple bonds. Exemplary alkyl, alkenyl and alkynyl groups herein include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, n-butyl, sec-butyl, tert-butyl, isopentyl, neopentyl, tert-pentyl, isohexyl, allyl (propenyl) and propargyl (propynyl). Substitutions may include, but are not limited to, halo, pseudohalo, alkyl, alkoxy, cycloalkyl, aryl, heteroaryl, amino, hydroxy, alkoxycarbonyl, hydroxycarbonyl, and fluorescent fatty acids, for example, dipyrromethene boron difluoride (BODIPY), 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD), dimethylaminonaphthalenesulfonate (Dansyl), pyrene, rhodamine, courmarin, or fluorescein.
- As used herein, “aryl” refers to aromatic monocyclic or multicyclic groups containing from 6 to 19 carbon atoms. Aryl groups include, but are not limited to groups such as unsubstituted or substituted phenyl and unsubstituted or substituted naphthyl.
- As used herein, “heteroaryl” refers to a monocyclic or multicyclic aromatic ring system, in certain embodiments, of about 5 to about 15 members where one or more, in one
embodiment 1 to 3, of the atoms in the ring system is a heteroatom, that is, an element other than carbon, including but not limited to, nitrogen, oxygen or sulfur. The heteroaryl group may be optionally fused to a benzene ring. Heteroaryl groups include, but are not limited to, furyl, imidazolyl, pyrimidinyl, tetrazolyl, thienyl, pyridyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolinyl and isoquinolinyl. - As used herein, “halo” refers to F, Cl, Br or I.
- As used herein, pseudohalides or pseudohalo groups are groups that behave substantially similar to halides. Such compounds can be used in the same manner and treated in the same manner as halides. Pseudohalides include, but are not limited to, cyanide, cyanate, thiocyanate, selenocyanate, trifluoromethoxy, and azide.
- As used herein, “cycloalkyl” refers to a saturated mono- or multi-cyclic ring system, in certain embodiments of 3 to 10 carbon atoms, in other embodiments of 3 to 6 carbon atoms.
- As used herein, “hydroxycarbonyl” refers to —COOH.
- As used herein, “alkoxycarbonyl” refers to —C(O)OR in which R is alkyl, including lower alkyl.
- As used herein, “alkoxy” refers to RO— in which R is alkyl, including lower alkyl. As used herein, “amino” refers to H2N— and “hydroxyl” refers to HO—.
- As used herein, “aralkyl” refers to an alkyl group in which one of the hydrogen atoms of the alkyl is replaced by an aryl group.
- As used herein, “heteroaralkyl” refers to an alkyl group in which one of the hydrogen atoms of the alkyl is replaced by a heteroaryl group.
- As used herein, pharmaceutically acceptable derivatives of a compound include salts, esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, solvates, hydrates or prodrugs thereof. Such derivatives may be readily prepared by those of skill in this art using known methods for such derivatization. The compounds produced may be administered to animals or humans without substantial toxic effects and either are pharmaceutically active or are prodrugs. Pharmaceutically acceptable salts include, but are not limited to, amine salts, such as but not limited to N,N′-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1′-ylmethyl-benzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc; and other metal salts, such as but not limited to sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, nitrates, borates, methanesulfonates, benzenesulfonates, toluenesulfonates, salts of mineral acids, such as but not limited to hydrochlorides, hydrobromides, hydroiodides and sulfates; and salts of organic acids, such as but not limited to acetates, trifluoroacetates, maleates, oxalates, lactates, malates, tartrates, citrates, benzoates, salicylates, ascorbates, succinates, butyrates, valerates and fumarates. Pharmaceutically acceptable esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl and heterocyclyl esters of acidic groups, including, but not limited to, carboxylic acids, phosphoric acids, phosphinic acids, sulfonic acids, sulfinic acids and boronic acids. Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more solvent or water molecules, or I to about 100, or 1 to about 10, or one to about 2, 3 or 4, solvent or water molecules.
- As used herein, treatment means any manner in which one or more of the symptoms of a disease or disorder are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein, such as use for treating diseases or disorders in which caveolar endocytosis, PM microdomain formation, transmembrane signaling, or integrin function is implicated.
- As used herein, amelioration of the symptoms of a particular disorder by administration of a particular compound or pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.
- As used herein, the abbreviations for any compounds or biological compositions, are, unless indicated otherwise, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (see, (1972) Biochem. 11:942-944).
- Compositions of Matter
- This disclosure is directed to the use of non-natural sphingolipids, the compounds of Formula I, for the inhibition of caveolar endocytosis, plasma membrane microdomain formation, transmembrane signaling and integrin function, including for the treatment, prevention, or amelioration of a disease associated with these cellular functions. The disclosure demonstrates that certain SLs, including those with D-erythro or D-threo stereochemistry, may regulate caveolar endocytosis by inducing the clustering of integrins and other transmembrane (TM) proteins into PM domains, resulting in their activation and transmembrane signaling. The compounds of Formula I, on the other hand, prevent PM microdomain formation and inhibit integrin signaling and caveolar endocytosis. For example, in one embodiment, a compound of Formula I, C8-LT-LacCer, selectively blocks β1-integrin clustering and activation in HSFs, and may inhibit superoxide production in combination with IL-5 treatment in human eosinophils. Accordingly, the use of the compounds of Formula I can be extended to other cells types where inhibition of caveolar endocytosis, PM microdomain formation, transmembrane signaling and integrin function may have significant effects on inflammatory responses (e.g., asthma, allergy), cell migration and invasiveness (e.g., of cancerous or precancerous cells), and infection by certain bacteria, fungi, and viruses.
- In one embodiment, the compounds for use in the compositions and methods provided herein have Formula I:
where the stereochemistry atcarbons 2 and 3 can be (2S,3S) (i.e., L-threo), (2R,3S) (i.e., L-erythro), (2S,3R) (i.e., D-erythro), or (2R,3R) (i.e., D-threo); R1 can be C1-25 alkyl, C2-25 alkenyl, C2-25 alkynyl, C2-25 aralkyl, C2-25 heteroaralkyl, (C1-20 alkyl)X, (C2-20 alkenyl)X; or (C2-20 alkynyl)X; X can be any fluorophore; R2 can be C1-25 alkyl, C2-25 alkenyl, C2-25 alkynyl, C2-25 aralkyl, or C2-25 heteroaralkyl. - In certain embodiments, R3 can be a carbohydrate or substituted choline derivative. Examples of carbohydrates include monosaccharides (e.g., glucose, fructose, ribose, and galactose), disaccharides (e.g., sucrose, lactose, and maltose), oligosaccharides, gangliosides, carbohydrates containing one or more sialic acid residues (e.g., 1, 2, 3, or 4 sialic acid residues), and carbohydrates containing sulfate esters. In some embodiments, R3 is selected from the group consisting of the formulae:
In further embodiments, R1 is a C1-25 alkyl (e.g., C1-10, C2-12, C4-16, C8-10, Cl10-12, C8-12, C12-16, C14-16, C11-15, C13-16, C10-20, C12-24, C8-22, C15-25, and C18-24). In other embodiments, R1 is a C8-22 alkyl. In other embodiments, R1 is (C1-5 alkyl)X. In further embodiments, X is selected from boron dipyrromethenedifluoride (BODIPY), 7-(4-nitrobenzo-2-oxa-1,3-diazole) (NBD), dimethylaminonaphthalenesulfonate (Dansyl), pyrene, rhodamine, courmarin, or fluorescein. In some instances, X is BODIPY. In certain embodiments, R2 is a C5-20 alkyl (e.g., C5-10, C6-12, C5-7, C10-15, C6-9, C8-14, C11-15, C10-20, C12-18, C14-20, C17-19, and C16-20). In some embodiments, R3 is a group of the formula:
In still further embodiments, the compound of Formula I is β-D-lactosyl-N-ocatnoyl-L-threo-sphingosine or C8-L-threo-lactosylceramide (C8-LT-LacCer).
In other embodiments, the compound of Formula I is C8-L-erythro-lactosylceramide (C8-LE-LacCer). In another embodiment, the compound of Formula I is C8-L-threo-galactosylceramide (C8-LT-GalCer).
In certain embodiments, the compound of Formula I is C8-L-erythro-galactosylceramide (C8-LE-GalCer). In other embodiments, the compound of Formula I is C8-L-threo-globoside (C8-LT-Gb3).
In further embodiments, the compound of Formula I is C8-L-erythro-globoside (C8-LE-Gb3). In some embodiments, the compound of Formula I is C8-L-threo-sphingomyelin (C8-LT-SM).
In certain embodiments, the compound of Formula I is C8-L-erythro-sphingomyelin (C8-LE-SM). In further embodiments, the compound of Formula I is C6-L-threo-sphingomyelin (C6-LT-SM).
In other embodiments, the compound of Formula I is C6-L-erythro-sphingomyelin (C6-LE-SM). In one embodiment, the compound of Formula I is C8-L-threo-monosialohexosylganglioside (C8-LT-GM4).
In another embodiment, the compound of Formula I is C8-L-erythro-monosialohexosylganglioside (C8-LE-GM4). In certain embodiments, the compound of Formula I is C8-L-threo-monosialodihexosylganglioside (C8-LT-GM3).
In certain embodiments, the compound of Formula I is C8-L-erythro-monosialodihexosylganglioside (C8-LE-GM3).
In some embodiments, the compound of Formula I is C8-L-threo-monosialotetrahexosylganglioside (C8-LT-GM1).
In other embodiments, the compound of Formula I is C8-L-erythro-monosialotetrahexosylganglioside (C8-LE-GM1). In another embodiment, the compound of Formula I is C5-BODIPY-L-threo-lactosylceramide (C5-BODIPY-LT-LacCer).
In further embodiments, the compound of Formula I is C5-BODIPY-L-erythro-lactosylceramide (C5-BODIPY-DE-LacCer) or C5-BODIPY-D-threo-lactosylceramide (C5-BODIPY-LT-LacCer). - The compositions of this disclosure may be prepared by the procedure described by Liu, Y. et al. (see, Liu, Y. and Bittman, R. Chem. Phys. Lipids 2006, 142, 58.) In certain embodiments, the procedure may be modified as required to obtain the desired compounds. In one embodiment of the disclosure, the implementation of an appropriate acid may be used to obtain the correct substitution at R1 (e.g., octanoic acid), various terminal alkynes may be used to account for the variation in R2 (e.g., 1-pentadecyne), and the formula used at R3 may be obtained through modification of reaction conditions, known to one of ordinary skill in the art, to obtain the appropriate configuration of the suitably activated glycosyl donor (e.g., trichloroacetimidate, molecular sieves and a solution of BF3.Et2O in CH2Cl2 stirred overnight to obtain the lactosyl functionality).
- In some embodiments, the compositions provided herein may be further modified into a pharmaceutical composition, and may exist as a pharmaceutically acceptable salt or derivative. The pharmaceutical compositions provided herein contain therapeutically effective amounts of the compounds provided herein that is useful in the treatment or amelioration of one or more of the symptoms of diseases or disorders associated with caveolar endocytosis, PM microdomain formation, transmembrane signaling and integrin function, or in which caveolar endocytosis, PM microdomain formation, transmembrane signaling and integrin function is implicated, and a pharmaceutically acceptable carrier. Diseases or disorders associated with caveolar endocytosis, PM microdomain formation, transmembrane signaling and integrin function include, but are not limited to, inflammatory diseases and cancer. Pharmaceutical carriers suitable for administration of the compounds provided herein includes any such carriers known to those skilled in the art to be suitable for the particular mode of administration.
- In addition, the compound may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients.
- The compounds are, in one embodiment, formulated into suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for parenteral administration, as well as transdermal patch preparation, dry powder inhalers, or aerosols. In one embodiment, a compound as described above is formulated into a pharmaceutical composition using techniques and procedures well known in the art (see, e.g., Ansel Introduction to Pharmaceutical Dosage Forms, Fourth Edition 1985, 126).
- In the compositions, effective concentrations of a compound or pharmaceutically acceptable derivative thereof is mixed with a suitable pharmaceutical carrier. The compound may be derivatized as the corresponding salt, ester, acetal, ketal, orthoesters hemiacetal, hemiketal, acid, base, solvate, or hydrate. The concentrations of the compound in the composition is effective for delivery of an amount, upon administration, that treats or ameliorates one or more of the symptoms of diseases or disorders associated with integrin function or in which integrin function is implicated.
- In one embodiment, the compositions are formulated for single dosage administration. To formulate a composition, the weight fraction of compound is dissolved, suspended, dispersed or otherwise mixed in a selected carrier at an effective concentration such that the treated condition is relieved or one or more symptoms are ameliorated.
- The active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective concentration may be determined empirically by testing the compounds in in vitro and in vivo systems and then extrapolating to dosages for humans.
- The concentration of active compound in the pharmaceutical composition will depend on absorption, inactivation and excretion rates of the active compound, the physicochemical characteristics of the compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art. For example, the amount that is delivered is sufficient to ameliorate one or more of the symptoms of diseases or disorders associated with integrin function or in which integrin function is implicated, as described herein.
- The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
- In instances in which the compound exhibits insufficient solubility, methods for solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN®, or dissolution in aqueous sodium bicarbonate. In certain embodiments, the compound of Formula I may be utilized with a carrier. Potential carriers may include alcohol, DMSO, serum album, and artificial lipid vesicles (e.g., Liposomes), which may or may not contain other lipids (e.g., phosphatidylcholine). This latter method may be particularly useful in certain embodiments where in vivo delivery via airways is utilized.
- Derivatives of the compounds, such as pharmaceutically acceptable salts of the compounds may also be used in formulating effective pharmaceutical compositions.
- Upon mixing or addition of the compound(s), the resulting mixture may be a solution, suspension, emulsion, or the like. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for ameliorating the symptoms of the disease, disorder or condition treated and may be empirically determined.
- The pharmaceutical compositions are provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds or pharmaceutically acceptable derivatives thereof. The pharmaceutically therapeutically active compounds and derivatives thereof are, in one embodiment, formulated and administered in unit-dosage forms or multiple-dosage forms. Unit-dose forms as used herein refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Examples of unit-dose forms include ampoules and syringes and individually packaged tablets or capsules. Unit-dose forms may be administered in fractions or multiples thereof. A multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pints or gallons. Hence, multiple dose form is a multiple of unit-doses which are not segregated in packaging.
- Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.
- Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975.
- Methods of Use of the Compounds and Compositions
- Provided herein are methods to inhibit caveolar endocytosis, PM microdomain formation, transmembrane signaling and integrin function through contact of cells with a compound of Formula I.
- In certain embodiments, the exposure of cells to a compound of Formula I results in an inhibition of caveolar endocytosis, PM microdomain formation, transmembrane signaling, and/or integrin function within exposed cells. Introduction of the composition can be made in vivo or in vitro and may include incubation or exposure of the cells to a pure compound of Formula I, or may instead include other compounds or solutions (e.g., water, buffers, antibodies, interleukins, fluorescently-labeled cellular components, alcohols, DMSO, serum album, liposomes, and/or lipids). Any cell type may be used, and may include fibroblasts, eosinophils, epithelials, ciliated, muscle, erythrocytes, leukocytes, neurons, oligodendrocytes, stem cells, as well as cancer cells from, for example, ovarian, small lung cell carcinomas, glioblastoma, and prostate tumors. A change or modulation to the aforementioned cellular functions may be determined through the comparison of cellular function within similar cells which have been left untreated, as a control, or exposed to an SL of known function, for example, C8-DE-LacCer.
- In some embodiments, inhibition of cellular functions may include inhibition of one or more of the following: plasma membrane microdomain formation; integrin clustering and activation within plasma membrane microdomains; caveolar endocytosis, src kinase activity, superoxide production, and degranulation. In certain embodiments, the integrin inhibited by a compound of Formula I may include, but is not limited to, those listed in Table 1 (adapted from Faull, R. J. and Ginsberg, M. H., J. Am. Soc. Nephrol 1996, 7, 1091.). For example, treatment of HSFs with C8-LT-LacCer, inhibits β1-integrin, preventing caveolar endocytosis.
TABLE 1 The Integrin Familya (adapted from Faull, R. J. et al., J. Am. Soc. Nephrol. 1996, 7, 1091.) Integrin Alternative Name(s) Ligand(s) Distribution α1β1 VLA-1, CD49a/CD29 Collagen, laminin Broad α2β1 VLA-2, CD49b/CD29 Collagen, laminin Broad α3β1 VLA-3, CD49c/CD29 Laminin-5, fibronectin, Broad collagen α4β1 VLA4, CD49d/CD29 Fibronectin, VCAM-1 Lymphocytes, muscle, monocytes/macrophages, neutral crest cells, fibroblasts α5β1 VLA-5, CD49e/CD29 Fibronectin Broad α6β1 VLA-6, CD49f/CD29 Laminin, fertilin Broad α7β1 VLA-7 Laminin unknown α8β1 VAL-8 Firbronectin, Neutral vitronecting, tenascin α9β1 VLA-9 Tenascin unknown αvβ1 Fibronectin, Epithelial cells cittronectin αLβ2 LFA-1, CD11a/CD18 ICAM-1, ICAM-2, Leukocytes ICAM-3 αMβ2 Mac-1, CD11b/CD18 Fibrogen, IC3b, Monocytes, granulocytes, ICAM-1, factor X natural killer cells, cytotoxic T lymphocytes αXβ2 p150, 95, CD11c/CD18 Fibrinogen, IC3b Monocytes, granulocytes, activated B lymphocytes αllbβ3 gpllb/llla Fibrinogen, Platelets, megakaryocytes fibronectin, vWF, vittronectin αvβ3 VnR Fibrinogen, Endothelium, tumor cells fibronectin, vWF, vittronectin, Thrombosponsin, osteoppontin, collagen α6β4 Laminin-1, laminin-5 Epithelial cells αvβ5 Vitronectin, fibronectin Carcinoma cells αvβ6 Fibronectin unknown α4β7 VCAM-1, fibronectin, Actibated B and T MadCAM-1 lymphocyes, monocytes/macrophages αEβ7 E-cadherin Intraepithelial lymphocytes αvβ8 Vitronectin unknown
aVCAM-1, vascular cell adhesion molecule-1; ICAM, intercellular adhesion molecule; IC3b, Inactivated complement component C3; vWF, con Willebrand factor; MadCAM-1, mucosal addressin cell-adhesion molecule.
- In another embodiment, the composition of Formula I can be used to treat, prevent, or ameliorate one or more symptoms of a disease associated with caveolar endocytosis, PM microdomain formation, transmembrane signaling, and/or integrin function in a mammal (e.g., a human, dog, pig, monkey, cat, mouse, rat, or horse). For example, inhibition of caveolar endocytosis could have significant effects on inflammatory responses, or the mobility of cancerous or precancerous cells. Diseases associated with an inflammatory response can include allergies, Alzheimer's, anemia, aortic valve stenosis, arthritis, cancer, congestive heart failure, fibromyalgia, fibrosis, heart attack, kidney failure, lupus, pancreatitis, psoriasis, stroke, and surgical complications. Caveolar endocytosis may also participate in the proliferation of various types of cancer (e.g., breast cancer, prostate cancer, skin cancer, lung cancer, leukemia, colon cancer, and Non-Hodgkin Lymphoma). Further applications of the compound of Formula I may include blocking the uptake and/or binding of particular pathogens by cells, as caveolae have been implicated in the uptake of certain viruses (e.g., SV40), toxins (e.g., chlolera toxin B subunit), fungi, bacteria, SLs, and albumins in various cell types.
- In a further embodiment, the composition of Formula I may be used to treat, prevent, or ameliorate one or more symptoms of a disease associated with integrin function in a mammal. Diseases linked to integrin function may include Multiple Sclerosis (see, e.g., Sheremata W. A. et al., CNS Drugs 2005; 19(11), 909), prothrombotic risk (see, e.g., Vijayan, K. V and Bray, P. F., Exp. Biol. Med. 2006, 231(5), 505), ulcerative colitis (see, e.g., Ferraccioli, G. F. et al., Eur. Rev. Med. Pharmacol., Sci. 2006, 10(1), 37), and renal disease (see, e.g., Blattner, S. M. and Kretzler, M., Curr Opin. Nephrol. Hypertens. 2005, 14(4), 404).
- In one embodiment of this disclosure, a compound of Formula I may be used to study cellular processes, for example, caveolar endocytosis. These lipids may be used to modulate plasma membrane microdomain formation and therefore the downstream processes reliant on this functionality. Inhibition may be initiated through exposure (e.g., contact, addition, etc) of cells to a compound of Formula I either in vitro or in vivo. In certain embodiments, additional components may be used in conjunction with the lipid to further explore cellular functions (e.g., antibodies, interleukins, fluorescently-labeled cellular components, and biological inhibitors of cellular processes). In some embodiments, a compound of Formula I may be used in conjunction with a test compound to determine if the test compound is capable of restoring an inhibited function (e.g., caveolar endocytosis or uptake of a pathogen) while in the presence of a compound of Formula I. Any appropriate cells may be used with a compound of Formula I, depending on the purpose of the study. For example, eosinophils may be used to study the role of PM microdomain formation in the inflammatory response, while skin fibroblasts may be used to investigate the role of this process on various endocytic events. In addition, a compound of Formula I might be particularly effective in modulating tumor cell motility and invasiveness since integrins bind to extracellular matrix proteins and cell surface ligands and are responsible for many types of cell adhesion events. For these studies, cancer cells from ovarian, small lung cell carcinomas, glioblastoma, and prostate tumors may be particularly useful.
- Previous work has demonstrated that acute treatment of cells with exogenous GSLs (natural or synthetic; all with natural D-erythro (DE) stereochemistry, including C8-DE-LacCer) or elevation of cellular cholesterol dramatically and selectively stimulated caveolar endocytosis without affecting other endocytic mechanisms (see, e.g., Sharma, D. K. et al., Molec. Biol. Cell 2004, 15, 3114 and Sharma, D. K. et al., Cancer Res. 2005, 65, 1). Importantly, no stimulation was seen when cells were treated with other classes of lipids and stimulation was not due to degradation of the exogenous GSLs.
- The non-natural (L-threo; LT) isomers of C8-LacCer and BODIPY-LacCer were synthesized. The latter was synthesized by the method detailed in Liu, Y., et al. Chem. Phys. Lipids, 2006, 142, 58 (referred to as Liu). C8-LT-LacCer was prepared through a modification of the methods used in Liu, where an activated for of octanoic acid was used in place of BODIPY-C5-NHS. HSFs were then either untreated (Control) or treated for 30 min at 10° C. with D-erythro (DE) or L-threo (LT) C8-LacCer, and then pulse labeled with fluorescent albumin or anti-β1-integrin Fab (caveolar markers), Tfn (clathrin marker), dextran (fluid phase marker), or anti-IL2R Fab (for RhoA pathway). After 5 min at 37° C., cells were acid-stripped to remove non-internalized marker and images were acquired by fluorescence microscopy (A) and quantified (B). At least 20 cells for each condition were analyzed in multiple experiments. Bar, 10 μm.
- The LT-lipid inhibited uptake of multiple caveolar markers in HSFs, as shown in
FIG. 2 ; compare C8-LT-LacCer (yellow bars) to the corresponding DE isomer (red bars), which stimulated caveolar uptake as noted above. Furthermore, in contrast to BODIPY-DE-LacCer which is internalized via caveolae (see, e.g., Singh et al., J. Biol. Chem. 2006, in press), BODIPY-LT-LacCer was internalized primarily (˜65-70%) by clathrin-dependent endocytosis (data not shown). This result is particularly significant because selective inhibition of this pathway may have important applications in basic studies of endocytosis and in blocking uptake of particular pathogens by cells. - A potential mechanism for C8-LT-LacCer inhibition of caveolar endocytosis, namely disruption of PM microdomain formation, was explored. This mechanistic possibility was tested through incubation of cells with AF594-CtxB at 10° C. to label GM ganglioside at the PM, followed by an anti-Ctx-B IgG. This treatment caused the formation of numerous micron-sized clusters of Ctx-B at the PM which were not present in the absence of Ab (
FIG. 3A , left vs. middle). Importantly, when cells were pretreated with LT-LacCer for 30 min at 10° C. prior to incubation with the labeled CtxB and crosslinking Ab, no clustering of PM domains was observed (FIG. 3A , right). No inhibition of domain formation was observed using C8-DE-LacCer; rather the DE isomer induced the formation of large domains enriched in GM1 ganglioside and cholesterol, in the absence of a crosslinking Ab (see, e.g., Singh, R. D., et al., 2006, submitted). - CV1 cells were then incubated at low temperature with SV40 virus and it was found that this treatment induced the formation of PM domains enriched in GM1 ganglioside and cholesterol, (
FIG. 3B ,C, left vs. middle) remarkably similar to the clustered microdomains induced by CtxB crosslinking (FIG. 3A ). Interestingly, pretreatment of CV1 cells with C8-LT-LacCer prevented the SV40 induction of these PM domains (FIG. 3B ,C, right panels). These results provide a potential explanation for the reduction in SV40 binding to CV1 cells since GM1 ganglioside is a receptor for SV40 (see, e.g., Norkin, L. C. and Kuksin, D.,Virol. J 2005, 3, 38; and Tsai, B. et al., EMBO. J. 2003, 22, 4346) and clustering of GM1 may be required for maximal SV40 binding. - Together, these experiments demonstrate that the induction of PM domains by various treatments (crosslinking Abs or SV40) is prevented by C8-LT-LacCer. This modulation of PM domain organization may disrupt the selection of cargo for subsequent caveolar uptake.
- A further mechanistic possibility by which C8-LT-LacCer might inhibit caveolar internalization is by disruption transmembrane signaling events required for endocytosis. Signaling through β1-integrin was studied because this integrin is internalized via caveolae in HSFs and other cell types (see Sharma, D. K. et al., Cancer Res. 2005, 65, 8233; and Upla, P. et al., Mol. Biol. Cell 2004, 15, 625), and because an early event following integrin activation is signaling through src, a kinase whose activity is required for caveolar endocytosis (see, e.g., Mineo, C. and Anderson, R. G., Histochem. Cell Biol. 2001, 116, 109; Sharma, D. K. et al., Cancer Res. 2005, 65, 8233; and Arias-Salgado, E. G. et al., Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13298). The first examination involved the activation of β1-integrin in HSFs following crosslinking with a stimulatory Ab (β1-stim Ab) using the HUTS-4 Ab which only binds to β1-integrins in their activated conformation (see, e.g., Luque, A. et al., J. Biol. Chem. 1996, 271, 11067). Treatment with the stimulatory Ab dramatically increased HUTS binding (
FIG. 4 ), while pretreatment with C8-LT-LacCer prior to incubation with β1-stim Ab reduced HUTS binding to levels seen in untreated control cells. In contrast, when C8-DE-LacCer was used, the Ab-induced activation of β1-integrin was not inhibited. When C8-LT-LacCer was incubated with HSFs in the absence of β1-stim Ab, no increase in HUTS binding was seen (data not shown). This is in contrast to C8-DE-LacCer which activated β1-integrin in the absence of the β1-stim Ab, to a similar extent as when the Ab was used alone (data not shown). - Since β1 integrins have been shown to activate src kinases and src phosphorylation is required for caveolar endocytosis (see, e.g., Sharma, D. K. et al., Mol. Biol. Cell 2004, 15, 3114; and Arias-Salgado, E. G. et al., Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13298), the effect of C8-LT-LacCer treatments on these processes were also examined. Cells were incubated for 30 min at 10° C.± the LacCer stereoisomers and/or the β1-stim Ab followed by a 30 sec incubation at 37° C. Cell lysates were then immunoblotted for src and phospho-(Y416) src. Src kinase was activated (phosphorylated at Y416) by treatment with C8-DE-LacCer to a level similar as that seen with the stimulating antibody and this activation could be blocked by the src inhibitor, PP2 (
FIG. 5 ). In contrast, little or no src activation was observed upon treatment with C8-LT-LacCer. Furthermore, pretreatment of cells with C8-LT-LacCer inhibited src phosphorylation induced by the β1-stim Ab, while pretreatment with C8-DE-LacCer did not significantly affect src phosphorylation in response to β1-stim (data not shown). - Human eosinophils were purified from normal individuals or patients with mild allergy by Percoll density gradient centrifugation and magnetic cell sorting using MACS anti-CD16 microbeads as described by Hansel T. T., et al., J. Immunol. Methods 1991, 145, 105. Briefly, after peripheral blood was overlaid on an isotonic Percoll solution (1.084 g.ml, Sigma), the blood was centrifuges at 1000×g for 30 min at 4° C. Mononuclear cells at the interface were removed, and erythrocytes in sediment were lysed by two cycles of hypotonic water lysis. Isolated granulocytes were washed twice in PIPES buffer (25 mM PIPES, 50 mM NaCl, 5 mM KCl, 25 mM NaOH, 5.4 mM glucose, pH 7.4) containing 1% alpha calf serum (HyClone Laboratories; Logan, Utah). Cells were then incubated with equal volume of anti-CD16 mAb MACS microbeads for 60 min at 4° C. with occasional gentle mixing. After 60 min of incubation on ice, cells were loaded onto the separation column positioned in the MACS magnetic field. Cells were eluted three times with 5 ml of PIPES buffer with 1% DCS. The purity of eosinophils counted by Randolph's stain was >98%. The contaminating cells were neutrophills, and no mononuclear cells or basophils were present. Purified eosinophils were used immediately for experiments.
- Superoxide anion generation and degranulation by human eosinophils were used as readouts of eosinophils functions in response to proteases or synthetic PAR activating peptides. Generation of superoxide by eosinophils was measured by superoxide dismutase-inhibitable reduction of cytochrome c as previously described with slight modifications. Freshly isolated eosinophils were washed and resuspended in Hank's balanced salt solution (HBSS) with 25 mM HEPES and 0.01% gelatin (Sigma) and 100 mM cytochrome c at 5×105 cells/ml. Cell suspension (100 μl) was dispensed onto the wells of 96-well tissue culture plates, followed by 100 μl of serial dilution of C8-DE-LacCer or medium alone. Immediately after addition of stimuli, the reaction wells were measured for absorbance at 550 nm in a microplate autoreader (Thermomax, Molecular Devices, Menlo Park, Calif.), followed by repeated readings. Between absorbance measurements, the plate was incubated at 37° C. After incubation and repeated measurements of superoxide production at 37° C. and 5% CO2 for 4 h, cell-free supernatants from 96-well tissue culture plates were collected, and stored at −20° C. until assayed for eosinophils degranulation. To quantitate eosinophils degranulation, the concentrations of eosinphil-derived neutrotoxin (EDN) in the sample supernatants were measure by specific RIA.
- C8-DE-LacCer induces adhesion of eosinophils to tissue culture wells. Eosinophils incubated with C8-DE-LacCer were flattened and showed spindle shape with many pseudopods, suggesting integrin-mediated cellular adhesion. A large quantity of superoxide was produced by eosinophils stimulated with C8-DE-LacCer but not those incubated with medium alone. Furthermore, a granule protein, EDN, was released into supernatants by eosinophils incubated with C8-DE-LacCer. Given the effects of C8-DE-LacCer on eosinophils superoxide anion generation and adhesion, it is anticipated that C8-LT-LacCer may have inhibitory effects on some of these processes.
- To define the molecular features of GSL analogs and their ability to selectively internalize by caveolar endocytosis, the structure of the natural D-erythro-LacCer compound was modified (Singh, R. D., et al. Mol. Biol. Cell, 2003, 14, 3254). The modifications included those to the structure of the fluorescent lipid through variations to its carbohydrate headgroup, chain length of the sphingosine base, or chain length of the fluorescent fatty acid (see
FIG. 6 ). Tests were designed to test initial internalization and sensitivity to inhibitor treatments. - To investigate the structural determinants of GSLs that result in selective internalization via caveolae, the structure of the fluorescent GSL analogs were systematically varied (see
FIG. 6 ) and examined to determine the effect of these variations on the mechanism of analog internalization. To examine the significance of the carbohydrate head group, the fluorescent analogs of GalCer, globoside, GM1, LacCer, MalCer, and sulfatide were used. For each of these fluorescent GSL analogs, the fluorescent fatty acid and sphingosine base were identical (n′=3, n=7;FIG. 6A ). Rat fibroblasts (RFs) were incubated with each analog in the presence or absence of various inhibitors to differentiate clathrin-dependent from clathrin-independent endocytosis, and the amount of internalization (at 5 min) was quantified by image analysis. The internalization of each GSL analog (GalCer, globoside, GM1, LacCer, MalCer, and sulfatide) was substantially inhibited by nystatin (but not by chlorpromazine (CPZ)), similar to BODIPY-LacCer (see Table 2), indicating that the specific carbohydrate headgroup structure or the stereochemistry of the glycosidic linkage in the disaccharide moiety of the GSL does not play a significant role in selective internalization of these GSLs by the clathrin-independent, caveolar mechanism. - A control experiment was carried out exactly as above, except that BODIPY-LacCer was introduced into cells from an ethanolic solution rather than from a BSA complex. As seen in Table 2, virtually identical results were obtained when the LacCer analog was delivered to RFs using BSA vs. ethanol injection, indicating that the BSA carrier did not influence the LacCer uptake mechanism.
- Furthermore, the importance of hydrophobicity on the mechanism of GSL endocytosis was examined. For these studies, the BODIPY-LacCer analogs that were used varied the chain length of the sphingosine base (C12 to C20), or fatty acid (C3 vs. C5 spacer) (n=1, 5, 7, or 9; n′=1 or 3;
FIG. 6A ). Endocytosis of the series of LacCer analogs was studied in RFs as above, but surprisingly none of the modifications in chain length affected the mechanism of LacCer internalization. To investigate the possible influence of the BODIPY fluorophore, the internalization of NBD-labeled LacCer was studied, and it was found that its internalization was nystatin-inhibitable and CPZ-insensitive (see Table 2), similar to our findings for BODIPY-LacCer (and other BODIPY-GSLs). This demonstrated that the fluorophore (NBD vs. BODIPY) had no apparent influence on the internalization mechanism. - Finally, a comparison between NBD-LacCer and NBD-D-PC (see
FIG. 6B )was made to study the possible influence of the lipid backbone (ceramide vs. glycerol) on the internalization mechanism. As shown in Table 2, the endocytosis of NBD-D-PC was found to be predominantly CPZ-inhibitable, suggesting that unlike LacCer, its uptake occurred largely by clathrin-dependent endocytosis. - These structural studies suggest that GSL uptake via caveolae is not selective for a specific carbohydrate headgroup, acyl chain hydrophobicity, or fluorophore substitution; however, comparison with the uptake of NBD-D-PC suggests that the ceramide core of GSLs may play an important role in caveolar endocytosis of GSLs. For further experimental details, see, e.g., Marks, D. L. et al., Methods 2005, 36, 186-195; and Singh, R. D., et al., Curr. Prot. Cell. Bio. 2006, in press).
TABLE 2 Inhibition of lipid analog endocytosis by different biochemical treatments in rat fibroblasts Clathrin-independent Clathrin-dependent Fluorescent internalization internalization lipid Nystatin Genistein Chloropromazine K+-depletion analog % % % % BODIPY- 71.9 ± 9.5 ND 10.5 ± 2.8 ND GalCer BODIPY- 75.1 ± 6.8 73.9 ± 4.1 9.3 ± 1.7 10.4 ± 1.3 LacCer BODIPY- 76.7 ± 8.2 ND 9.2 ± 1.9 ND MalCer BODIPY- 82.6 ± 10.5 82.0 ± 4.5 0.7 ± 0.1 7.0 ± 0.8 Globoside BODIPY- 78.2 ± 7.6 73.6 ± 9.7 9.1 ± 2.2 ND Sulfatide BODIPY- 74.7 ± 8.2 69.9 ± 8.9 8.8 ± 1.2 11.6 ± 2.1 GM1 NBD-LacCer 75.6 ± 6.7 ND 15.1 ± 2.4 ND NBD-D-PC 20.4 ± 4.4 ND 71.3 ± 8.5 ND - The effect of C8-LT-LacCer treatment on SV40 infection in monkey CV1 cells was examined as endocytosis of this virus has been extensively characterized in this cell type and shown to occur via caveolae (Pelkman, L., et al. Nature Cell Biol. 2001, 3, 473; Anderson, H. A., et al., Mol. Biol. Cell 1996, 7, 1825; Stang, E., et al. Mol. Biol. Cell 1997, 8, 47.) CV1 cells were pretreated with the LacCer stereoisomers and SV40 at low temperature, washed, and shifted to 37° C. for 14 hrs. Pretreatment of cells with C8-LT-LacCer dramatically reduced the vial infection as monitored by the expression of the large T antigen, while C8-DE-LacCer had no effect relative to untreated control samples (see
FIG. 7A , B). - Since inhibition of SV40 infection by C8-LT-LacCer could result from effects on virus binding as well as endocytosis, we also studied the effect of C8-LT-LacCer on SV40 binding. Cells were treated with the C8-LT-LacCer isomer and SV40 at low temperature, washed, and then incubated with a monoclonal antibody to the SV40 major capsid protein VP1. C8-LT-LacCer inhibited SV40 binding to CV1 cells by about 80% (see
FIG. 7C , D). - A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
Claims (58)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/839,024 US8263576B2 (en) | 2006-08-15 | 2007-08-15 | Non-natural sphingolipid analogs and uses thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83802406P | 2006-08-15 | 2006-08-15 | |
US90890307P | 2007-03-29 | 2007-03-29 | |
US11/839,024 US8263576B2 (en) | 2006-08-15 | 2007-08-15 | Non-natural sphingolipid analogs and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080064645A1 true US20080064645A1 (en) | 2008-03-13 |
US8263576B2 US8263576B2 (en) | 2012-09-11 |
Family
ID=39170479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/839,024 Active 2029-06-10 US8263576B2 (en) | 2006-08-15 | 2007-08-15 | Non-natural sphingolipid analogs and uses thereof |
Country Status (1)
Country | Link |
---|---|
US (1) | US8263576B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012168342A1 (en) * | 2011-06-06 | 2012-12-13 | Ulrich Dietz | Biopassivating membrane stabilization by means of nitrocarboxylic acid-containing phospholipids in preparations and coatings |
US11559568B2 (en) * | 2017-10-27 | 2023-01-24 | Children's Medical Center Corporation | Short chain ceramide-based lipids and uses thereof |
US11771771B2 (en) | 2018-04-12 | 2023-10-03 | Children's Medical Center Corporation | Ceramide-like lipid-based delivery vehicles and uses thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2933554A1 (en) * | 2013-12-12 | 2015-06-18 | The Brigham And Women's Hospital, Inc. | Treating neurodegenerative disease |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5936076A (en) * | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
US6017892A (en) * | 1992-07-16 | 2000-01-25 | Kiran Beer Kabushiki Kaisha | Method for accelerating marrow cell proliferation |
US6204002B1 (en) * | 1996-10-22 | 2001-03-20 | Daikin Industries, Ltd. | Gangliosides having fluorescent-tagged ceramide moieties |
US6417167B1 (en) * | 1997-02-05 | 2002-07-09 | Kirin Beer Kabushiki Kaisha | Lyophilized compositions containing shingoglycolipid and process for preparing them |
US6747010B2 (en) * | 1997-04-10 | 2004-06-08 | Kirin Beer Kabushiki Kaisha | NKT cell-activating agents containing α-glycosylceramides |
-
2007
- 2007-08-15 US US11/839,024 patent/US8263576B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5936076A (en) * | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
US6017892A (en) * | 1992-07-16 | 2000-01-25 | Kiran Beer Kabushiki Kaisha | Method for accelerating marrow cell proliferation |
US6204002B1 (en) * | 1996-10-22 | 2001-03-20 | Daikin Industries, Ltd. | Gangliosides having fluorescent-tagged ceramide moieties |
US6417167B1 (en) * | 1997-02-05 | 2002-07-09 | Kirin Beer Kabushiki Kaisha | Lyophilized compositions containing shingoglycolipid and process for preparing them |
US6747010B2 (en) * | 1997-04-10 | 2004-06-08 | Kirin Beer Kabushiki Kaisha | NKT cell-activating agents containing α-glycosylceramides |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012168342A1 (en) * | 2011-06-06 | 2012-12-13 | Ulrich Dietz | Biopassivating membrane stabilization by means of nitrocarboxylic acid-containing phospholipids in preparations and coatings |
US11559568B2 (en) * | 2017-10-27 | 2023-01-24 | Children's Medical Center Corporation | Short chain ceramide-based lipids and uses thereof |
US11771771B2 (en) | 2018-04-12 | 2023-10-03 | Children's Medical Center Corporation | Ceramide-like lipid-based delivery vehicles and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US8263576B2 (en) | 2012-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schrezenmeier et al. | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology | |
Carlsson et al. | Inhibition of ethanol-induced excitation in mice and rats by α-methyl-p-tyrosine | |
Zimmerman et al. | Neuropeptides promote neutrophil adherence to endothelial cell monolayers | |
US8404669B2 (en) | Kinase modulating compounds and uses thereof for treatment of cancer | |
AU742468B2 (en) | Methods for treatment of conditions associated with lactosylceramide | |
CN108042811A (en) | For treating the conjugate of the disease as caused by PSMA expression cells | |
AU1916401A (en) | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors | |
US8263576B2 (en) | Non-natural sphingolipid analogs and uses thereof | |
CN103108651A (en) | Inhibition of cyp3a drug metabolism | |
JPH01254623A (en) | Cancer treatment agent containing inhibitor of sphingoglycolipid metabolism as effective component | |
AU2013286823A1 (en) | Immunological reagents and uses therefor | |
Berman et al. | Brevetoxins cause acute excitotoxicity in primary cultures of rat cerebellar granule neurons | |
JP6981961B2 (en) | Fucosidase inhibitor | |
US20230122940A1 (en) | Combination therapy for treating cancer | |
JPH06509059A (en) | PMN-derived CR3 modulators and their uses | |
WO1995033467A2 (en) | Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications | |
Terada et al. | XO increases neutrophil adherence to endothelial cells by a dual ICAM-1 and P-selectin-mediated mechanism | |
US20100035940A1 (en) | Cyclin Dependent Kinase Inhibitors | |
US20090105281A1 (en) | Methods of treating inflammation | |
US11517581B2 (en) | Zika virus protease inhibitors and methods of use thereof | |
CN101415431A (en) | A method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same | |
Säwe et al. | Glucuronidation of morphine in human liver and interaction with oxazepam | |
Rowin et al. | Intracellular calcium requirements for β1 integrin activation | |
Ali-Osman et al. | Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas | |
Shao et al. | Nine-valent oleanolic acid conjugates as potent inhibitors blocking the entry of influenza A virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PAGANO, RICHARD E.;BITTMAN, ROBERT;MARKS, DAVID L.;AND OTHERS;REEL/FRAME:020179/0633;SIGNING DATES FROM 20071015 TO 20071127 Owner name: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PAGANO, RICHARD E.;BITTMAN, ROBERT;MARKS, DAVID L.;AND OTHERS;SIGNING DATES FROM 20071015 TO 20071127;REEL/FRAME:020179/0633 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH;REEL/FRAME:021148/0790 Effective date: 20071005 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |